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I I .  ABSTRACT  
The aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor highly expressed 
within the immune and nervous system. Structurally diverse endogenous and synthetic ligands 
activate AhR, including dietary, microbial and physiological compounds, suggesting a potential 
crosstalk between AhR’s signaling, diet, microbiome, and immune system. The aim of the 
present thesis was to evaluate if endogenous AhR ligands influence the development of 
spontaneous CNS autoimmunity. For this purpose, double transgenic opticospinal (OSE) mice 
carrying myelin oligodendrocyte glycoprotein (MOG) specific T and B cell receptors were 
generated with or without AhR competent dendritic cells (DC), CD4+ T cells, regulatory T cells 
(Tregs) or astrocytes. The spontaneous EAE incidence significantly increased in OSE animals 
with AhR deleted in DC (OSE AhRDC), but not in OSE mice devoid of AhR in CD4+ T cells, 
Tregs or astrocytes. OSE AhRDC CX3CR1EGFP/+ reporter mice were generated in order to assess 
the antigen presenting cells (APCs) of the lamina propria (LP), where MOG specific CD4+ T 
cells are likely activated in the OSE mouse model. AhR deficiency of DC increased the 
frequency of CX3CR1int DC and correspondingly decreased the frequency of CX3CR1- DC. 
The presence of CX3CR1int DC and CX3CR1- DC was confirmed by immunohistochemistry in 
the LP of CD11ctdTomato CX3CR1eGFP reporter mice. CX3CR1int DC showed higher MHCII 
expression than CX3CR1- DC. Thus, might be better equipped to initiate the activation of MOG 
specific naïve T cells. Compared to OSE AhRfl/fl control littermates, OSE AhRDC mice showed 
higher frequencies of IFNγ+ transgenic CD4+ T cells in the LP and increased MOG specific 
IgG2a antibodies in the sera. Furthermore, supplementing a single AhR ligand to the diet of 
OSE mice, spontaneous EAE was almost completely abolished. Finally, it was aimed to define 
the relevant cellular players mediating the therapeutic efficacy of the presumed and clinically 
relevant AhR agonist, Laquinimod, against EAE. Laquinimod significantly protected AhRDC, 
AhRCD4, AhRTreg and AhRAstro mice, but its protective effect was less sustained in AhRDC 
mice. In summary, this work provides evidence showing that the physiological concentrations 
of AhR ligands modulate CNS autoimmunity via AhR competent DC. 
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1 Introduction 
1 .  I NTRO DUCTION 
1.1 Multiple sclerosis 
Multiple sclerosis (MS) is a currently incurable chronic inflammatory and demyelinating disease 
of the central nervous system (CNS). It is considered autoimmune in nature and its cause 
remains unknown. MS is characterized by lymphocytic and monocyte/macrophage infiltrates 
wreaking havoc to the myelin sheaths and oligodendrocytes1. Inflammatory demyelination is 
associated with axonal and neuronal pathology, which are considered the major pathological 
determinants of irreversible neurological disability. 
Around 80% of MS patients start with a relapsing remitting (RRMS) clinical course, 
which is characterized by episodes of neurological dysfunction followed by recovery periods. 
Patients typically present initially vision problems, numbness and or muscle weakness2. With 
time, 65% of the RRMS patients enter a secondary progressive (SPMS) stage of the disease, 
characterized by a gradual physical decline with no noticeable remissions. A primary 
progressive (PPMS) disease course can be found in 15-20% of the MS cases and usually 
starts in male patients after the age of 403. 
1.1.1 MS Epidemiology  
MS is the most frequent inflammatory demyelinating disorder with a prevalence that varies 
considerably between regions with high rates in North America and Europe (less than 100 per 
100 000 inhabitants) and low rates in eastern Asia and sub-Saharan Africa (2 per 100 000). In 
addition, MS is considered the most frequent non-traumatic disorder leading to neurological 
disability in young adults4.  
As the most prevalent inflammatory disorder of the CNS, MS affects more than 2 million 
people worldwide5. The highest prevalence occurs in Europe where more than half of the 
diagnosed MS patients live6,7. Just in Germany, there are an estimated 100 to 140 thousand 
MS patients, which are generally diagnosed around the age of 35 years8.  
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Similar to other autoimmune disorders, MS is more prevalent in women than men; 
suggesting a role of sexual hormones, as well as gender differences in genes, development 
and function of the immune and nervous system3,9. The female-male ratio has significantly 
increased in the last decades (2.3-3.5:1). This significant increase of MS in women could be 
caused by environmental changes and nutrition10. 
1.1.2 MS Etiology 
Since Jean-Martin Charcot first described MS in 1868, its etiology has been extensively studied 
in order to design possible therapies that allow us to treat and ultimately cure the disease11. 
However, MS remains incurable up to now and the precise factors initiating the development 
of the disease are unclear.  
Like most autoimmune diseases, MS is considered a multifactorial disorder with genetic 
and environmental risk factors. Furthermore sex, age, race, cultural and socio-economic 
conditions might enter the intricate interaction of elements triggering the disease12. MS 
complexity probably resides in the fact that none of these factors is essential or sufficient to 
trigger or at least, to predict the disease. 
1.1.2.1 Genetic risk factors 
Recent studies conclude that genetic variation might be accountable for about 50% of the 
individual differences in MS susceptibility13,14. Different population-based studies have shown 
MS concordance rates for monozygotic twins (~25%), dizygotic twins (~5.4%) and siblings 
(~3%)15–20. 
Having a first degree relative with MS increases the risk up to 2 – 4%, which is already 
20 – 40 times higher than the 0.1% prevalence in the general population21. The likelihood to 
develop MS increases around 5– fold when both parents have the disease (12.2%) compared 
to one parent affected (2.5%)22–27. 
The first identified MS genetic risk locus was the major histocompatibility complex 
(MHC) on chromosome 6p21, specifically the human leukocyte antigen HLA-DR2 or 
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DRB1*1501-DQB1*0602 extended haplotype. This extremely polymorphic region has shown 
the most consistent association with MS by genome wide association studies (GWAS) and 
case-control studies.  
Carrying one copy of the HLA-DRB1*1501 haplotype increases the risk to develop MS 
2-3 fold, while carrying two copies elevates the risk by 6–fold15,28–30. Interestingly, other HLA 
alleles have been confirmed as MS protective factors including HLA-C554, HLA-DRB1*11, 
HLA A*02 and HLA B*44023,31. 
At present, more than 50 non-HLA genetic risk factors for MS have been discovered 
and most belong to genes affecting the immune response. Namely, interleukin 2 receptor α 
chain (IL2RA), interleukin 7 receptor α chain (IL7RA), CD58, C-Type Lectin Domain Containing 
16A (CLEC16A), nuclear receptor NR1.H3 and enzyme 1α-hydroxylase CYP27B1 (involved in 
vitamin D metabolism) are additional susceptibility genes for MS32–36. 
1.1.2.2 Environmental risk factors 
Since Charcot detected the variability in the incidence of MS around the world in 1877, plenty 
of evidence has been gathered regarding the environmental factors that could make an 
individual more susceptible to develop MS37. More than two decades ago, Kurtzke defined 
prevalence regions due to the geographically asymmetric distribution of MS38,39.  
Nowadays, latitudinal gradients have been identified in Europe, North America, 
Australia and Asia concerning MS geoepidemiology6,40–46. The greater number of MS cases in 
higher latitudes compared to lower ones supports the importance of environmental factors 
modulating MS onset. For instance, vitamin D assimilation, exposure to ultraviolet (UV) 
radiation, smoking and pathogens have been related to the risk of developing MS47. 
1.1.2.3 Vitamin D 
Due to the inverse correlation between MS prevalence and sunlight exposure and given the 
fact that UV light is essential for vitamin D3 (cholecalciferol) synthesis in the skin, vitamin D 
deficiency has been long considered a modifiable risk factor for MS48–50. Vitamin D and solar 
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radiation have been shown to play differential effects on the immune cells located in the 
skin51,52.The vitamin D receptor (VDR) is expressed in most cells of the human body, is 
involved in numerous cell processes and protects against autoimmune diseases36,53–56.  
Even though the most important source of vitamin D is induced by sun exposure in the 
skin, this fat soluble steroid can be also obtained from the diet and supplements57. The precise 
role of the vitamin D, as well as the diet’s impact on MS susceptibility have not been fully 
elucidated, however both have been suggested to play a role in the disease since the early 
50’s58,59.  
1.1.2.4 Diet 
Diet habits have been long associated to MS, particularly the fat60,61, salt62–64 and fiber 
consumption65–67. A large longitudinal study from 2012 reported that the Mediterranean diet 
prevents white matter lesions and cognitive decline by protecting small vessels in the brain68. 
This type of diet has been associated with reduced MS risk because it involves a high intake 
of fruits, vegetables, fish, whole grains, legumes and nuts69–71.  
Although there is no particular diet recommended for MS patients, following a healthy 
nutritional scheme has been positively associated with the composition of gut bacteria and the 
immune system homeostasis67,72–78. Besides nutritional status, obesity79–81, malnutrition82 and 
related disorders, such as dyslipidemia83 and hypertension84 have been connected with MS. 
1.1.2.5 Viral infections 
Among the environmental factors, viral infections caused by herpesviruses, namely the human 
herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV), have been associated to MS 
pathogenesis. The former is linked to MS due to a greater appearance of HHV-6 in MS lesions 
compared to MS normal appearing white matter possibly indicating that HHV-6 can be 
reactivated during MS relapses85,86.  
EBV is implicated in the pathogenesis of MS due to universal seropositivity and high 
anti-EBV antibody levels compared to age matched controls85,87–89. Furthermore, defective 
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control of EBV infection by cytotoxic CD8+ T cells might predispose to MS by allowing EBV-
infected autoreactive B cells to accumulate in the central nervous system87,90.  
Another hypothesis postulates that after viral infection, activated T cells recognize CNS 
antigens due to molecular similarity or mimicry. Nevertheless, this hypothesis extends to T 
cells primed in the periphery by any other infectious antigen or superantigen91,92. 
Despite the fact no single environmental factor has been proven to cause MS, all 
mentioned environmental factors are able to directly or indirectly modulate immune responses 
and to influence protein and gene expression possibly affecting the likelihood to develop MS. 
1.2 Experimental Autoimmune Encephalomyelitis 
Experimental autoimmune encephalomyelitis (EAE) is the most commonly used animal model 
for MS. It can be induced by active immunization with myelin proteins/peptides emulgated in 
complete Freund’s adjuvant (CFA) or by the adoptive transfer of myelin specific T cells into 
syngenic recipients92,93.  
Active EAE is achieved by immunization with myelin peptides depending on the mouse 
strain94. For example, the proteolipid peptide (PLP) is used for SJL/J mice immunization95, 
myelin oligodendrocyte glycoprotein (MOG) for C57BL/6 mice96,97 and myelin basic protein 
(MBP) for B10.PL mice98.  
In order to increase disease incidence, pertussis toxin is often administered at the time 
of the immunological challenge and two days later99. On the other hand, passive EAE is 
induced by adoptive transfer of encephalitogenic T cells, which can be in vitro manipulated 
before being inoculated to the recipients. The autoreactive T cells could be also labeled to 
follow their localization and interactions with other cells100. 
Alternatively, spontaneous EAE can be observed in myelin specific T cell receptor 
transgenic mice. The frequency of spontaneous EAE can be significantly increased in animal 
strains less prone to EAE development such as C57BL/6 mice by generating MOG specific T 
and B cell receptor transgenic mice such as the opticospinal (OSE) mice. In contrast to single 
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transgenic animals, around 50% of the OSE mice develop spontaneous EAE in the first 10 
weeks of age depending on the housing conditions101,102.  
Environmental factors vary depending on the animal facility and shape the microbiota 
composition, propensity to develop infections and immune responses. It is thought that 
external stimuli could trigger the autoimmune conversion of innocuous progenitors to 
pathogenic immune cells, leading to the combined attack of pathogenic T and B cells that 
potentially prompt spontaneous EAE development in the OSE mice103. 
The EAE model is considered a CD4+ or T helper (Th) cell mediated autoimmune 
disease that resembles MS features. For instance, CD4+ T cell and mononuclear cell infiltration 
with subsequent demyelination and clinical signs. CD4+ Th1 and Th17 cells are primed outside 
the CNS before crossing the blood brain barrier (BBB). Besides microglia activation and other 
inflammation mediators’ attraction, IFNγ production by Th1 cells and IL17 by Th17 cells causes 
damage in the myelin covering the axons92. 
Activation of MOG specific T cells in the gut-associated lymphatic tissue (GALT) is 
necessary for spontaneous EAE development in the relapsing remitting (RR) mice (SJL/J 
strain). According to Berer and colleagues103 the commensal microbiota could provide innate 
immune signals or peptides that share similarities with MOG epitopes. Their observations in 
germ free (GF) mice demonstrated full protection through life against spontaneous EAE in the 
RR mice, supporting a central role of commensal microbiota shaping CD4+ T cell priming at 
the GALT. 
In general, no animal model recapitulates all features and underlying mechanisms of 
any human disorder. However, the EAE experimental model has been widely used to identify 
therapeutic targets and molecular pathways relevant in MS pathophysiology104. 
1.3 Gut immune system 
The gastrointestinal tract is the largest mucosal surface that separates the organism from the 
external environment. It comprises trillions of microorganisms termed the gut microbiome, 
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which have co-evolved with the host over millennia in a symbiotic relationship105. The 
microbiota composition differs between individuals and performs essential functions to 
maintain the gut homeostasis, metabolism and immune system106. 
The microbial community contains between 1000 to 1500 species depending on 
environmental and genetic factors. Most of them are Bacteroides and Firmicutes (92%), that 
offer different metabolic benefits to the host and vice versa107. For instance, the host provides 
a nutritive milieu and a suitable niche for colonization, whereas the gut microbiota contributes 
to the assimilation of nutrients, development of the epithelium and immune system, as well as 
modulation of innate and adaptive immune responses, among many others108. 
The intestinal wall is covered by finger-like protrusions called villi, whose major function 
is nutrient absorption and transport through its network of blood vessels. Nevertheless, these 
structures and the underlying tissues are also hosting the largest population of immune cells 
in mammals. The gut immune system coordinates a delicate balance directing immune 
responses against invading pathogens and providing tolerance to harmless microbes and food 
to avoid autoimmunity109.  
The gut mucosa is formed by a single layer epithelium and the connective tissue 
beneath, which is known as the lamina propria (LP). The epithelial cells or enterocytes line up 
the lumen of the intestines and together with the overlying mucus are the first point of contact 
with food and microbes. Enterocytes are intercalated by intraepithelial lymphocytes (IEL), with 
about one lymphocyte for every four to nine epithelial cells110. 
IEL comprise roughly equal numbers of αβ and γδ T cells. They are a very 
heterogeneous group that includes: natural IEL, activated during development in the thymus 
in the presence of self-antigens and induced IEL, activated post-thymically in response to 
peripheral antigens. Both express activation markers such as CD69+ and CD44+111.  
Natural IEL are either CD8αα+ or CD8αα- T cells that express γδ or αβ TCR but do not 
express CD4+ or CD8αβ+ (CD8- CD4- double negative cells), whereas induced IELs arise from 
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conventional αβ TCR CD4+ or CD8αβ+ T cells. The natural IEL are the dominant T cell 
population in unchallenged mice. These cells enter the small intestine directly after 
maturation110–112. 
Secondary lymphoid structures are scattered along the gut mucosa and embedded in 
the LP forming the gut associated lymphoid tissue (GALT). Most of the GALT encloses 
dispersed leukocytes in diffuse masses under the gut epithelium. In some cases, leukocytes 
are arranged in more organized structures such as the Peyer´s patches (PP). These dome-
like organs are surrounded by a follicle-associated epithelium containing B cell follicles with 
germinal centers and interfollicular T cell areas113.  
PP are considered gut immune sensors because of their ability to transport luminal 
antigens and bacteria through specialized phagocytic M (microfold) cells114. The matrix of the 
PP comprises T cells and the three major APCs types: macrophages, B cells and DC, 
increasing the probability of antigen uptake right after its release by M cells. Another 
mechanism of luminal sampling is executed by DC in the PP and LP, which extend their 
processes across the epithelial layer into the gut lumen. Once a DC has engulfed a bacterial 
antigen, it will then migrate through the lymphatic circulation to the closest mesenteric lymph 
node to present its antigenic cargo70. 
Pattern recognition receptors (PRR) activate DC and define the type of cytokines that 
they produce. These cytokines will then modulate the differentiation of naïve T cells into 
proinflammatory or regulatory lineages. Most intestinal CD4+ T cells are located in the LP. Even 
though they are activated by DC via antigen recognition in the context of MHCII, specific 
microbial stimulus can activate diverse differentiation programs characterized by particular 
transcription factors: Th1 (T-bet), Th2 (Gata-3), Th17 (Rorγt) or Tregs (FoxP3)108,115,116. 
Proinflammatory stimuli can be exerted by different pathogens. For example, 
Bacteroides fragilis has been shown to induce T cell differentiation into Th1 cells that secrete 
IFNγ117. Extracellular parasites promote a Th2 response with IL4, IL5 and IL13 secretion. 
Certain extracellular pathogens, such as segmented filamentous bacteria (SFB), stimulate 
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Th17 differentiation leading to IL17, IL17F and IL22 production118,119. Conversely, it was shown 
that colonization with Clostridium spp. of the large intestine favors Tregs  differentiation, which 
maintains a tolerogenic state by producing IL10, IL35 and TGFβ120,121. 
1.4 The aryl hydrocarbon receptor 
One putative MS therapeutic target is the aryl hydrocarbon receptor (AhR), which is a ligand 
activated transcription factor widely expressed in the immune and nervous system. Despite 
the fact it is best known for mediating the toxic effects of chemical pollutants its evolutionary 
conservation suggests that binding toxins might not be its primary function. As part of the basic 
helix-loop-helix/Per-Arnt-Sim (PAS) homology superfamily, the AhR is a promiscuous receptor 
that can be activated by structurally diverse agonists found in the environment or 
endogenously produced122,123.  
1.4.1 AhR is ubiquitously distributed 
Consistent with its role as environmental sensor, AhR is expressed in the liver and barrier 
tissues, such as gut, skin and lungs124,125. Within the nervous system it is found in neurons and 
glia, showing particularly high levels in astrocytes126,127. In the immune system, it is expressed 
in hematopoietic, innate, B and T cells128.  
High AhR expression has been reported in plasma cells, Th17, γδ T cells, innate 
lymphoid cells type 3 (ILC3), monocytes, macrophages, mast cells, dendritic cells (DC) and 
Langerhans cells76,129–135. In contrast, AhR expression is significantly weak in the kidneys, 
secretory glands, muscle and stromal cells123,124. 
1.4.2 AhR endogenous and exogenous ligands 
The AhR has been extensively studied in the toxicology field for its role during the 
biotransformation of different environmental pollutants. For example, the 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (TCDD) is the best known AhR xenobiotic ligand. However, a vast diversity 
of AhR ligands have been identified, including not only environmental toxins, but also dietary 
(obtained from vegetables, fruits and teas), commensal microflora and physiological 
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compounds. Some of the reported physiological AhR ligands are 6-formylindolo[3,2-
b]carbazole (FICZ), kynurenine and indoles136–139. 
1.4.3 AhR signaling pathway 
As an inactive protein, the AhR is located in the cytoplasm binding actin filaments and forming 
a multiprotein complex with the heat shock protein 90 (HSP 90), AhR-interacting protein (AIP), 
c-SRC protein kinase and the cochaperone p23. Upon ligand binding, the AhR undergoes a 
conformational change that allows it to bind importin β, to translocate into the nucleus and to 
release the complex123,136.  
In the active form, the AhR heterodimerizes with its interaction partner, AhR nuclear 
translocator (ARNT) and binds genomic regions containing the dioxin response element (DRE) 
motif. Hence, AhR induces the transcription of certain target genes, for example, AhR 
repressor (AhRR), indoleamine 2,3-dioxygenase 1 (IDO1), and enzymes corresponding to the 
cytochrome P450 (CYP) family, such as CYP1A1, CYP1A2 and CYP1B1137,140,141. 
1.4.4 AhR function 
The AhR is considered a key regulator of gene expression networks underlying homeostasis, 
developmental processes, physiological and immune responses. Exerting its effect in a wide 
range of tissues, the AhR expression is tightly regulated and its functions are cell specific and 
diverse128.  
Depending on the ligand, AhR stimulation can activate different pathways producing 
different effects in the EAE model. For example, it can strongly influence the development of 
proinflammatory Th17 or anti-inflammatory regulatory T cells (Tregs )142, maintain gut epithelial 
barrier integrity69,125 and modulate NK cell activation, innate lymphocyte cell (ILC) homeostasis 
and IL22 production72,143,144. At large, activation of the AhR pathway can modulate CNS 
inflammation integrating immunological, metabolical and environmental stimuli126,145. 
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1.4.5 AhR knock out animals 
In order to elucidate AhR functions and to provide a sensible animal model for this 
environmental sensor, three AhR knock out (KO) strains have been developed. During the 
90’s, independent groups from Spain, Japan and the USA generated separately AhR KO mice 
by gene targeting of exons 1 and 2 of the AhR locus. Different strategies were used to disable 
the murine AhR locus in vivo producing mice yielding some, though minor, dissimilarities in 
their phenotypes136.  
The group of Prof. Frank Gonzalez inactivated the AhR gene by replacing the exon 1 
containing DNA binding sites with a neomycin resistance gene146. 40-50% of these mice die 
postnatally. Furthermore, they often have lower splenocyte numbers, eosinophilia and 
lymphocyte infiltration of various organs. In addition, the liver of this mutant demonstrated 
glycogen depletion, hepatic fibrosis and inflammation of the bile ducts147. 
A second AhR null mutant was generated by Prof. Fujii-Kuriyama’s group replacing 
part of the exon 1 with the bacterial galactosidase gene148. These animals exhibit the highest 
postnatal lethality of all AhR KO mice (50%).  
The most widely used AhR KO strain was developed by Prof. Bradfield and 
collaborators (AhRtm1Bra). They targeted exon 2, which encodes the basic/helix-loop-helix 
domain, known to be required for DNA recognition and dimerization with ARNT149. Even though 
this strain has shown very low postnatal lethality, it presents other immune and hepatic defects 
such as smaller periarteriolar lymphatic sheets (PALS), larger spleens, prolonged 
extramedullary hematopoiesis and impaired hepatic fat metabolism150,151.   
  In a comparison between the three AhR deficient mutant lines published by Prof. Esser, 
they all share some features including liver pathology, decreased fertility, slower growth rate, 
elevated retinoic acid levels, TCDD resistance, a patent ductus venosus, and failure to induce 
CYP1A1 and CYP1A2. Noteworthy, AhR KO mice present a spectrum of hepatic defects due 
to the crucial role of AhR in liver growth and development. For instance, liver size is 
  
12 Introduction 
dramatically reduced to approximately half of the size of WT mice. Fibrosis is frequently 
observed and liver tumors develop in a proportion of the animals150. 
The AhR KO mouse strains have been crucial to elucidate AhR’s immunomodulatory 
functions that go beyond its role as an environmental sensor, including repercussions in 
development, reproduction, immunology and gut-microbiome interactions derived from AhR 
signaling122,152. For example, AhR KO mice helped to describe AhR’s role in peripheral 
myelination. AhR ablation in mice causes locomotor defects, induces thinner myelin sheaths 
and causes dysregulation of myelin gene expression and developmental markers in the 
peripheral nervous system153. 
1.4.6 AhR modulates the crosstalk between the intestinal immune system, diet and 
microbiota 
In the last decade, most attention on AhR research focused on its functions as master regulator 
of peripheral immunity affecting CNS inflammation and integrating environmental signals. AhR 
activity can be regulated by dietary components derived from cruciferous vegetables such as 
broccoli and Brussels sprouts69,76,154.  
The majority of dietary AhR ligands are plant derived compounds including flavonoids, 
glucosinolates, stilbenes, carotenoids and some indoles155. For example, indole-3-carbinol 
(I3C) uptake from ingested cruciferous vegetables leads to high affinity AhR ligands production 
in the stomach, such as indolo-[3,2-b]-carbazole (ICZ) and 3,3′-diindolymethane (DIM)156,157. 
 Most of these ligands are able to enter AhR expressing cells forming the intestinal 
epithelium and immune system. They trigger AhR nuclear translocation and targeted gene 
expression, including CYP1A1 and CYP1A2158.  
It has been shown that natural AhR ligands modulate Th17 cell differentiation in vivo 
and in vitro159. AhR signaling is required in Th17 T cells obtained from C57BL/6J mice to 
produce IL22130,160,161. CD4+ T cells from AhR KO mice can develop Th17 cells but when 
confronted with AhR ligands fail to produce IL22130. 
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In humans, AhR mediates IL22 production in Th22 cells162. IL22 is expressed at barrier 
surfaces by mouse and human cells and its signaling plays an important role in antimicrobial 
immunity, maintenance and inflammation of the bowel163.  
Another major source of IL22 is produced by cells from the ILC family, including NK 
and lymphoid tissue inducer (LTi) cells. In this way, AhR ligands derived from the diet or 
microbiota not only regulate IL22 production, but also the maintenance, survival and 
proliferation of Rorγt+ ILC in the gut and other mucosal barriers75,164,165. 
AhR expression in ILC3 has been relatively well studied in the gut because of its 
repercussions in other immune compartments. For instance, deletion of AhR in ILC3 impairs 
IL22 production decreasing the gut epithelial cells production of antimicrobial peptides. This 
proinflammatory stimulus leads to an increase of segmented filamentous bacteria (SFB) and 
induces Th17 responses143,144.  
AhR mediates the interaction between ILC3 and microbiota. Animals lacking caspase 
recruitment domain family member 9 (CARD9) present altered microbiota and are unable to 
metabolize tryptophan into AhR ligands. The catabolism of the essential amino acid tryptophan 
into kynurenine by the tryptophan 2,3-dioxygenase (TDO) or indoleamine 2,3-dioxygenase 
(IDO) provides a major source of AhR ligands. Therefore an impairment of tryptophan 
metabolism in the microbiota causes a decrease in the ILC3 and consequently, in IL22 
production140,166,167. 
IDO1 can be induced in intestinal macrophages, epithelial and DC by different stimuli 
such as proinflammatory cytokines, toll like receptor ligands and interactions with costimulatory 
molecules. During infectious diseases IDO1 activity controls pathogen growth and Tregs 
expansion by metabolizing the available tryptophan into kynurenine. IDO1 response could 
either inhibit bacteria proliferation through amino acid – deprivation or modulate T cell response 
by generating tryptophan metabolites and AhR ligands168. 
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AhR’s genomic activity via tryptophan derived ligands could lead to IDO1 transcription 
via AhR responsive elements binding169. Besides acting as a transcription factor, AhR can act 
as E3 ubiquitin ligase and assemble with cullin 4B to form the ubiquitin ligase CUL4BAHR 
complex. Different proteins are targeted by this complex for proteasomal degradation, such as 
IDO1141, β catenin170, estrogen and androgen receptors171,172.  
AhR expression is essential for tertiary lymphoid tissue formation such as 
cryptopatches and intestinal lymphoid follicles155 and is involved in the proliferation of colonic 
crypt stem cells. Therefore, AhR deficiency has a significant impact on the gut immune system 
leading to ILC3 and IEL loss, impairment of IL22 secretion, disruption of the intestinal 
epithelium and dysregulation of intestinal bacteria136,173. 
1.4.7 EAE modulation by AhR ligands 
AhR activation during EAE induction has different repercussions in the immune system 
depending on the ligand. Stimulation at the time of EAE induction with the endogenous AhR 
agonist FICZ increased the number of IL17 and IL22 producing CD4+ T cells quantified in the 
spinal cord of C57BL/6J mice. In contrast, MOG35-55 immunized AhR KO animals showed a 
reduced production of IL17 and no IL22 was detectable regardless of FICZ stimulation130,160,161.  
Differently from FICZ stimulation, AhR activation by 2-(1′H- indole-3′-carbonyl)-
thiazole-4-carboxylic acid methyl ester (ITE) suppressed EAE in MOG35-55 immunized 
C57BL/6J mice. Daily administration of ITE from the day of immunization induced tolerogenic 
DC that supported the differentiation of FoxP3+ Tregs174. 
Besides the non-toxic endogenous ligands (FICZ and ITE), the high-affinity AhR 
agonist TCDD has been tested in the EAE model. A single TCDD i.p. injection on the day 
before MOG35-55 immunization inhibited EAE inducing Tregs expansion, decreasing IL17 
secretion and producing higher levels of TGFβ. TCDD oral administration also prevented EAE 
development and had a dose dependent effect on EAE induction142. 
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AhR regulates inflammation by affecting different components of the immune system. 
AhR, as well as its target gene CYP1B1, are upregulated in astrocytes through type I 
interferons (IFN-I) signaling after active immunization with MOG35-55. Astrocytes stimulated with 
IFNβ activate the JAK1-STAT signaling pathway and induce AhR expression. Furthermore, 
the knock down of IFN-I in astrocytes reduced the AhR expression and induced EAE 
worsening, suggesting a role of interferons limiting CNS inflammation through AhR 
signaling126. 
Additionally, certain quinolone-3-carboximide based drugs intended for the treatment 
of autoimmune diseases and tested in the EAE model are effective AhR activators175. The 
protective effect of Laquinimod, Tasquinimod and Paquinimod against EAE is mediated by 
AhR and affect AhR battery genes in a distinct manner176,177. 
1.5 Laquinimod  
Laquinimod is an orally active quinoline-3-carboximide with AhR agonistic properties 
formulated as a potential DMT for MS178–181. It has been modified form its predecessor 
roquinimex (linomide) to increase efficacy in EAE models and improve its toxicological 
profile182–185. As a small synthetic molecule, Laquinimod has the ability to freely cross the BBB 
without requiring further active transport. It has a high bioavailability (80-90%) and a low rate 
of total clearance. It is quickly absorbed in the gut reaching its maximum concentration in the 
plasma within two hours after administration. Laquinimod is normally eliminated in the urine 
after being metabolized by the cytochrome P450 (CYP) isoenzyme, CYP3A4 in the liver 
microsomes180,186–188.  
 
Figure 1. Structure of Laquinimod and Roquinimex. Laquinimod (5-chloro-N-ethyl-4-hydroxy-1-
methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide), also known as ABR-215062 or nerventra, 
is structurally related to roquinimex (linomide). 
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1.5.1 Laquinimod mediated EAE suppression 
Preclinical studies demonstrated that Laquinimod treatment inhibits acute and chronic 
relapsing EAE in C57BL/6 and SJL/J mice, respectively. Inflammatory cell infiltration, spinal 
cord demyelination and axonal loss were significantly reduced by daily oral administration of 
Laquinimod from the day of immunization (preventive regimen) in MOG35-55 immunized 
C57BL/6 mice188,189.  
Moreover, VLA-4 mediated cell adhesion and proinflammatory cytokine production by 
Th1/Th17 responses were downmodulated in treated mice190. Laquinimod was shown to 
modulate the adaptive T cell response via its effect on the antigen presenting cell (APCs) 
compartment182. 
Similarly, EAE was abolished in SJL/N mice immunized with mouse spinal cord 
homogenate (MSCH) using daily oral dosage of Laquinimod183. Laquinimod was also shown 
to inhibit EAE in Lewis rats, preventing CD4+ T cells and macrophages to infiltrate into the CNS 
and favoring Th2/Th3 cytokines191,192. Using different EAE protocols, Laquinimod has shown 
immunomodulatory properties affecting different immune cells, for instance APCs and T cell 
compartments188. 
Experiments using AhR KO animals showed that Laquinimod’s therapeutic effect is 
completely abolished in the absence of AhR193. In addition, bone marrow chimera experiments 
demonstrated that AhR deletion in the immune system completely revokes the therapeutic 
effect of Laquinimod, while AhR deletion in the CNS partially affects Laquinimod’s protective 
effect in the EAE model194. These results suggest that Laquinimod might have additional 
neuroprotective properties. 
Besides its immunomodulatory effect, Laquinimod has shown neuroprotective actions 
such as brain-derived neurotrophic factor (BDNF) modulation195,196 and axonal protection189,197 
in the EAE model and MS patients. In the cuprizone induced demyelination model, Laquinimod 
prevented demyelination, oligodendroglial apoptosis, astrocytic activation and microglia 
infiltration189. 
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1.5.2 Clinical trials 
In phase II placebo – controlled trials, Laquinimod showed a tolerable safety profile in patients. 
Daily treatment led to a reduction in the number of enhancing MRI lesions compared to 
placebo198,199, leading to further studies. Thereafter, orally administered Laquinimod (0.6 or 1.2 
mg per day) was tested in three randomized phase III clinical trials, namely ALLEGRO, BRAVO 
and CONCERTO studies, all of them multinational, multicenter, double blind, and placebo-
controlled.  
The first two, ALLEGRO (Assessment of OraLLaquinimod in PrEventing ProGRession 
in Multiple SclerOsis) and BRAVO (Benefit-Risk Assessment of AVonex and LaquinimOd) 
trials, revealed Laquinimod’s clinical efficacy, including reduction of disability progression, 
relapse rate and the number of gadolinium enhancing lesions200–203.  
In a third study, CONCERTO204, the primary endpoint of significant treatment effect on 
3-month-confirmed disability progression was not achieved. However, from baseline to month 
15 and compared to placebo, Laquinimod significantly reduced the risk for the first relapse 
(28%), relapse rate (25%) and brain volume change (40%). 
1.6 Current MS therapies 
MS patients can be treated by corticosteroids, plasma exchange and disease modifying 
therapies (DMT). Oral or intravenous corticosteroids including methylprednisolone, 
dexamethasone, prednisone, prednisolone and betamethasone are commonly prescribed to 
MS patients primarily to manage acute exacerbations or relapses through their rapid anti-
inflammatory properties205.  
Plasma exchange or immune adsorption can be used in the short term to treat severe 
exacerbations if steroids are ineffective or contraindicated206,207. Disease modifying therapies 
(DMT) are prescribed to MS patients in order to reduce the number and the severity of 
relapses208. The currently accepted DMT are summarized in table 1. 
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Table 1. First and second line approved drugs for MS treatment. Abbreviations: ↓: reduction; ↑: 
increase; ARR: Annualized relapse rate; CCDMS: conversion to clinically definite multiple sclerosis; 
DMT: disease modifying treatment, DP: disability progression; INF: interferon; i.m.: intramuscular; i.v.: 
intravenous; s.c.: subcutaneous. 
The escalating and the induction therapies are the two major treatment approaches for 
MS. Mildly or moderately affected MS patients usually receive a first line therapy with moderate 
DMT (commercial 
name) 
Dosage/ 
Route/ 
Frequency 
Efficacy in 
clinical 
trials  
References 
Mechanism of 
action 
Drug 
class 
IFNβ 
– 1a 
(Avonex) 
30 mcg / 
i.m. / 
weekly 
↓18% ARR 
and ↓44% 
CCDMS 
CHAMPS209, 
CHAMPIONS210 
Different immuno-
modulatory 
effects 211 
First line 
– 1a (Rebif) 
44 mcg / 
s.c. / 3 x 
week 
↓32% ARR 
and ↓45% 
CCDMS 
ETOMS212 Different immuno-
modulatory 
effects 213 
First line 
– 1b 
(Betaseron) 
250 mcg / 
s.c. / every 
other day 
↓34% ARR, 
↓30% DP 
and ↓50% 
CCDMS  
BENEFIT198,214 
Different 
immunomodulator
y effects 215 
First line 
– 1b 
(Extravia) 
0.25 mg / 
s.c. / every 
other day 
↓42% ARR, 
↓16% DP 
and 
216–218 Immuno-
modulatory 
therapy for RRMS 
and SPMS 
First line 
Glatiramer acetate 
(Copaxone) 
20 mg / s.c. 
/ every day 
↓29% ARR 
and↓45% 
CCDMS 
219–221, 
PreCISe222, 
GLACIER223,  
Induces and 
activates T- 
lymphocyte 
suppressor cells 
First line 
Teriflunomide 
(Aubagio) 
14 mg / 
oral / daily 
↓31%-36% 
ARR, 
↓26%-32% 
DP 
TEMSO224,225, 
TOPIC226, 
TOWER227 
Pyrimidine 
synthesis 
inhibition in 
lymphocytes 
First line 
Dimethyl fumarate 
(Tecfidera) 
240 mg / 
oral / 2 x 
day 
↓44%-53% 
ARR, 
↓38% DP  
CONFIRM228, 
DEFINE229, 
ENDORSE230, 
ESTEEM231 
Induces apoptosis 
in activated T 
cells through Th2 
cytokines 
First line 
Natalizumab 
(Tysabri) 
300 mg / 
i.v. / 
monthly 
↓68% ARR, 
↓42% DP 
SENTINEL232, 
TIMER233, 
AFFIRM234,235 
Blockade of 
adhesion 
molecules that 
inhibit T cell traffic 
across the BBB 
Second 
line 
Fingolimod 
(Gilenya) 
0.5 mg / 
oral / daily 
↓48%-54% 
ARR, ↓30% 
DP  
TRANSFORMS 
236–239, 
FREEDOMS 
240,241, 
FREEDOMS 
II242 
S1PR receptor 
modulator and 
Immuno-
suppressant 
First line 
Alemtuzumab 
(Lemtrada) 
30 mg x 
day / i.v. / 3 
x week for 
12 weeks 
↓49%-55% 
ARR  
↓42% DP  
CAMMS223 
243,244, CARE 
MS I245, CARE 
MS II246 
Anti-CD52 
monoclonal 
antibody that 
depletes T and B 
lymphocytes  
Second 
line 
Mitoxantrone 
(Novantrone) 
12 mg/m2 x 
3 months 
or 8 mg/m2 
monthly / 
i.v.  
↓65% 
relapse risk 
and ↓66% 
DP  
247–249 DNA intercalator 
and 
topoisomerase II 
enzyme activity 
inhibitor 
Second 
line 
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efficacy but high safety profile before changing to a second line medication with more safety 
risks (escalating approach). The induction approach is the initial use of a highly effective 
second line treatment in order to obtain a rapid remission of a highly active disease250,251. 
1.7 Aims 
The AhR molecular pathway is activated by different environmental factors affecting the 
immune system. Contradicting results have been obtained using MOG35-55 immunized 
C57BL/6J mice by stimulation with different high affinity AhR agonists such as FICZ, ITE and 
TCCD130,142,174. It remains unknown if physiological concentrations of AhR ligands in the regular 
diet have immunomodulatory properties influencing spontaneous EAE incidence and severity 
and if so, which cell type is the most relevant player for AhR mediated modulation of the CNS 
autoimmunity.  
The central aim of this project is to evaluate the function of AhR in CNS autoimmunity 
and its modulation through physiological ligands found in the diet. In order to get an insight 
through the AhR’s mechanistic regulation, the present work intends to elucidate which cellular 
players are required to mediate the immunomodulatory effect of the clinically relevant AhR 
agonist, Laquinimod. 
In detail, the present thesis aims: 
a) To assess if EAE incidence and severity can be influenced by increasing the AhR 
ligands of cruciferous vegetables in the diet of OSE mice.  
b) To evaluate AhR’s immunomodulation in DC, CD4+ T cells and astrocytes by 
generating cell specific AhR KO mice in the OSE mouse model using the Cre-Lox 
system. 
c) To investigate how clinically relevant cell specific AhR deficiencies in OSE mice 
affect APCs activation, antibody production and T cell activation. 
d) To identify relevant AhR targets that mediate the therapeutic efficacy of the putative 
AhR ligand, Laquinimod, in CNS autoimmunity. 
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2 .  MAT ERIALS AND METHO DS 
2.1 Materials 
2.1.1 Reagents  
Reagent Supplier 
Agarose StarLab GmbH, Hamburg, Germany 
BD FACS Clean BD Biosciences, Franklin Lakes, NJ, USA  
BD FACS Flow BD Biosciences, Franklin Lakes, NJ, USA  
BD FACS Lysing Solution, 10x BD Biosciences, Franklin Lakes, NJ, USA  
BD FACS Shutdown Solution BD Biosciences, Franklin Lakes, NJ, USA  
BD Pharm Lyse, 10x BD Biosciences, Franklin Lakes, NJ, USA  
β-Mercaptoethanol Sigma Aldrich, St. Louis, MO, USA 
Boric acid  Merck Millipore, Darmstadt, Germany 
CaCl2 (calcium chloride) Sigma Aldrich, St. Louis, MO, USA 
Chloral hydrate  Merck Millipore, Darmstadt, Germany 
Cytofix  BD Biosciences, Franklin Lakes, NJ, USA  
Cytofix/Cytoperm BD Biosciences, Franklin Lakes, NJ, USA  
(DAPI) Diamidino-2-phenylindole, 1 mg/ml Thermo Scientific, Waltham, MA, USA 
DMEM (Dulbecco's Modified Eagle's medium) Sigma Aldrich, St. Louis, MO, USA 
dNTP (desoxynucleoside triphosphate) mix Thermo Scientific, Waltham, MA, USA 
DTT (Dithiothreitol) Sigma Aldrich, St. Louis, MO, USA 
EDTA (ethylenediamine tetraacetic acid) Carl Roth, Karlsruhe, Germany 
FCS (fetal calf serum) Sigma Aldrich, St. Louis, MO, USA 
Fluorescence mounting medium Dako, Deutschland GmbH, Hamburg 
FoxP3 Fixation/Permeabilization Concentrate eBioscience, San Diego, CA, USA 
FoxP3 Fixation/Permeabilization Diluent eBioscience, San Diego, CA, USA 
FoxP3 Permeabilization buffer, 10x eBioscience, San Diego, CA, USA 
GelRed nucleic acid gel stain, 10 000x Biotium, Fremont, CA, USA 
GeneRuler, 100 base pairs (bp) DNA ladder plus Thermo Scientific, Waltham, MA, USA 
Go-Taq DNA polymerase buffer, 5x Promega, Madison, WI, USA 
HBSS (Hank‘s buffered salt solution) Sigma Aldrich, St. Louis, MO, USA 
HCl (hydrochloric acid) Merck Millipore, Darmstadt, Germany 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
Sigma Aldrich, St. Louis, MO, USA 
H2O2 (oxygen peroxide) Sigma Aldrich, St. Louis, MO, USA 
H2SO4 (sulfuric acid) Sigma Aldrich, St. Louis, MO, USA 
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Reagent Supplier 
Ionomycin Sigma Aldrich, St. Louis, MO, USA 
Isopropyl alcohol Merck Millipore, Darmstadt, Germany 
Laquinimod 
Teva pharmaceutical industries Ltd., Netanya, 
Israel 
L-glutamine Sigma Aldrich, St. Louis, MO, USA 
Mannide monooleate Sigma Aldrich, St. Louis, MO, USA 
MEM (minimum essential medium) non-essential 
amino acids, 100x 
Sigma Aldrich, St. Louis, MO, USA 
MgCl2 (magnesium chloride) Promega, Madison, WI, USA 
NaCl (sodium chloride) Carl Roth, Karlsruhe, Germany 
Paraffin oil Carl Roth, Karlsruhe, Germany 
PBS (phosphate buffered salt solution) Sigma Aldrich, St. Louis, MO, USA 
Penicillin, 10000 units/streptomycin, 10 mg/ml Sigma Aldrich, St. Louis, MO, USA 
Percoll Sigma Aldrich, St. Louis, MO, USA 
Permeabilization/Wash buffer, 10x BD Biosciences, Franklin Lakes, NJ, USA  
PMA (phorbol 12-myristate 13-acetate) Sigma Aldrich, St. Louis, MO, USA 
PFA (paraformaldehyde) Merck Millipore, Darmstadt, Germany 
QIAzol Lysis Reagent Qiagen, Maryland, MD, USA 
RPMI 1640 (Roswell Park Memorial Institute 
1640) 
Sigma Aldrich, St. Louis, MO, USA 
SDS (sodium dodecyl sulfate) Sigma Aldrich, St. Louis, MO, USA 
Sodium pyruvate, 100 mM Sigma Aldrich, St. Louis, MO, USA 
TMB (3,3',5,5'-tetramethylbenzidine) substrate 
solution 
eBioscience, San Diego, CA, USA 
Tris (tris(hydroxymethyl)aminomethane) Carl Roth, Karlsruhe, Germany 
Trypan blue Sigma Aldrich, St. Louis, MO, USA 
Xylene 
Chemsolute, Th. Geyer GmbH & Co. KG, 
Renningen, Germany 
Table 2. Reagents used in the different experimental procedures.  
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2.1.2 Buffers and solutions  
Solution Components 
80% Percoll solution 80% Percoll in DMEMhigh-Glu 
Agarose gel 2% agarose in TBE (Tris/Borate/EDTA) buffer 
CFA (Complete Freund’s Adjuvant) 
85% paraffin oil  
15% mannide monooleate  
6.7 mg/ml mycobacterium tuberculosis H37R 
Chloral hydrate 14% anesthesia 14 g chloral hydrate in 100 ml bidistilled H2O 
DMEMhigh-Glu (Dulbecco's Modified 
Eagle's medium high glucose) 
4500 mg/L glucose 
2% FCS in DMEM 
ELISA blocking buffer 5% BSA in PBS  
ELISA wash buffer 0.05% Tween 20 in PBS 
ELISA stop solution 1 N H2SO4 in H2O 
FACS buffer 2% FCS in PBS 
Fixation buffer 4% paraformaldehyde (PFA) in PBS 
Immunization emulsifier  
1:1 (v/v) mixture of CFA (supplemented with 5 mg/ml 
H37Ra) and 2 mg/ml MOG35-55 in PBS 
Master mix (40% Percoll solution) 40% Percoll in DMEMhigh-Glu 
MACS buffer 
0.5% BSA  
2 mM EDTA in PBS 
Percoll gradient medium 
40 or 80% Percoll 
2% FCS 
DMEM, high glucose (4.5 g/L D-glucose) 
RPMIcomplete (Roswell Park Memorial 
Institute 1640 medium complete) 
RPMI 1640  
10% FCS  
1 mM sodium pyruvate 1x 
1x non-essential amino acids 
50 µM β-mercaptoethanol 
0.1 mg/ml streptomycin 
2 mM L-glutamine 
Small intestine digestion solution 
100 µl collagenase D (100 mg/ml) 
100 µl DNase I (100 mg/ml) 
10% FCS 
10 mM CaCl2  
20 ml DMEM  
Small intestine predigestion solution 
 
1mM DTT 
5 mM EDTA  
10% FCS  
500 ml HBSS  
Tail Lysis Buffer  
0.1 M Tris-HCl  
200 mM NaCl  
0.2% SDS (sodium dodecyl sulfate) 
5 mM EDTA in bidistilled H2O, adjusted pH = 8.5 
TBE (Tris/Borate/EDTA) buffer 
90 mM Tris, 
90 mM boric acid 
2 mM EDTA in bidistilled H2O 
Table 3. Buffers, cell culture media and solutions used for immunization, cell isolation and flow 
cytometry stainings.  
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2.1.3 Applied kits 
Kit Supplier 
High‐Capacity cDNA Reverse 
Transcription Kit with RNase Inhibitor 
Life Technologies GmbH, Darmstadt, Germany 
NucleoSpin RNA XS Kit Macherey-Nagel GmbH, Düren Germany 
Pan Dendritic Cell Isolation Kit (mouse) Miltenyi Biotec, Bergisch Gladbach, Germany 
qPCR Core Kit Eurogentec, Liège, Belgium 
Tyramide SuperBoost Alexa Fluor 488 kit  Invitrogen, Life Technologies, USA 
Table 4. Applied kits.  
 
2.1.4 Cell lines and bacteria  
Organism Supplier 
B16F10 melanoma cell line 
Generous gift from Prof. Evelyn Ullrich, Children’s 
Hospital, Department of Pediatric Hematology and 
Oncology, Goethe-University, Frankfurt, Germany 
Mycobacterium tuberculosis H37RA,  
non-viable 
DIFCO, Detroit, MI, USA 
Table 5. Cell lines and bacteria. 
 
2.1.5 Proteins 
Proteins / enzymes Supplier 
BSA (bovine serum albumin) SERVA Electrophoresis GmbH, Heidelberg, Germany 
Collagenase D Roche, Basel, Switzerland 
Golgi Stop BD Biosciences, Franklin Lakes, NJ, USA 
Go-Taq DNA polymerase Promega, Madison, WI, USA 
Ionomycin Sigma Aldrich, St. Louis, MO, USA  
DNase I Roche, Basel, Switzerland  
MOG35-55 (myelin oligodendrocyte 
glycoprotein amino acids 35-55) 
His-tag purified at the Institute of Neuropathology, 
Göttingen, Germany 
Proteinase K Roche, Basel, Switzerland  
PTX (Pertussis toxin) List biological laboratories, Campbell, CA, USA 
Trypsin, 0.05% Gibco/Invitrogen, Carlsbad, CA, USA 
Table 6. Proteins, enzymes and inhibitors.  
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2.1.6 Oligoucleotide primers  
Mouse line Name Oligonucleotide sequence (5’-> 3’) Gene 
2D2 
oIMR6711 
CCC GGG CAA GGC TCA GCC ATG CTC 
CTG 
TCR Vα3.2 
oIMR6712 
GCG GCC GCA ATT CCC AGA GAC ATC 
CCT CC 
TCR Jα18 
AhRfl/fl 
Ahrtm3.1Bra-forward GGT ACA AGT GCA CAT GCC TGC 
AhR exon 3 
Ahrtm3.1Bra-reverse CAG TGG GAA TAA GGC AAG GA 
AhRDC 
CD11cCre trans-
forward 
ACT TGG CAG CTG TCT CCA AG 
CD11cCre 
CD11cCre trans-
reverse 
GCG AAC ATC TTC AGG TTC TG 
AhRCD4 
CD4Cre trans-
forward 
GCG GTC TGG CAG TAA AAA CTA TC 
CD4Cre 
CD4Cre trans-
reverse 
GTG AAA CAG CAT TGC TGT CAC TT 
AhRAstro 
859 -forward GTG AAA CAG CAT TGC TGT CAC TT 
GFAPCre 
860-reverse GCG GTC TGG CAG TAA AAA CTA TC 
AhRTreg 
WT-forward CCT AGC CCC TAG TTC CAA CC 
FoxP3Cre 
WT-reverse AAG GTT CCA GTG CTG TTG CT 
Mutant-forward 
AGG ATG TGA GGG ACT ACC TCC TGT 
A 
Mutant-reverse TCC TTC ACT CTG ATT CTG GCA ATT T 
Th/+ 
8.18C5-forward TGA GGA CTC TGC CGT CTA TTA CTG T Anti-MOG 
IgH 8.18C5-reverse GGA GAC TGT GAG AGT GGT GCC T 
mIgH-forward 
ATT GGT CCC TGA CTC AAG AGAAGA 
TG Igh-J 
mIgH-reverse TGG TGC TCC GCT TAG TCA AA 
CX3CR1EGFP/+ 
CX3CR1 WT-
reverse 
CAG TGA TGC TGG GCT TCC 
CX3CR1 CX3CR1-forward TCA GTG TTT TCT CCC GCT TGC 
CX3CR1-KI-
reverse 
GTA GTG GTT GTC GGG CAG 
Table 7. Oligonucleotide primers used for transgenic mice genotyping. All primers were purchased 
from Eurofins MWG, Ebersberg, Germany. Abbreviations: 2D2 mice: MOG specific T cell receptor 
transgenic mice; CX3CR1: CX3C chemokine receptor 1 (fractalkine receptor); GFAP: Glial fibrillary 
acidic protein; FoxP3: forkhead box P3; Itgax: integrin alpha X; IgH: murine immunoglobulin heavy chain; 
hybridoma clone 8.18-C5 used to subclone the 1.7 kb genomic region containing a rearranged VHDJH 
gene and denominated Th gene; MOG: myelin oligodendrocyte glycoprotein; Th/+ mice: MOG specific 
B cell receptor transgenic mice. 
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2.1.7 Primers for qPCR 
Primer number 
RNA 
specificity 
Reference 
sequence 
Supplier 
Mm99999915_g1 GAPDH NM_001289726.1 
Life Technologies GmbH, 
Darmstadt, Germany 
Mm00487218_m1 CYP1A1 NM_001136059.2 
Table 8. TaqMan qPCR primers. Abbreviations: GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase; CYP1A1: cytochrome P450 enzyme, family 1, subfamily A, polypeptide 1. 
 
2.1.8 Secondary anti-mouse HRP tagged antibodies used for ELISA 
Name Antigen Dilution Host Supplier 
IgG1 STAR132P IgG1 1:4000 in 
0.5% BSA in 
PBS 
goat 
Bio-Rad AbD Serotec 
GmbH,  Puchheim, Germany 
IgG2a STAR133P IgG2A 
Table 9. Polyclonal antibodies used for ELISA. Horseradish peroxidase (HRP) tagged antibodies 
used to measure MOG antibody concentrations in blood serum samples. 
 
2.1.9 Primary antibodies used in paraffin embedded sections 
Name Antigen Dilution Host Supplier 
Anti-RFP polyclonal  
(#600-401-379S) 
RFP 1:100 
rabbit 
Rockland Immunochemicals, Inc., 
PA, USA 
Anti-GFP polyclonal 
(#PABG1-100) 
GFP 1:2000 
ChromoTek GmbH, Planegg-
Martinsried, Germany 
Table 10. Primary antibodies used in paraffin embedded sections.  
 
2.1.10 Secondary antibodies used in paraffin embedded sections 
Name Dilution Host Supplier 
Anti-rabbit IgG (H+L)-
biotinylated (#111-065-144) 
1:500 
goat 
Dianova GmbH, Hamburg, 
Germany 
Anti-rabbit IgG (H+L)- Cy3 
conjugated (#111-165-144) 
1:100 
Table 11. Secondary antibodies used in paraffin embedded sections.  
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2.1.11 Fluorophore tagged monoclonal antibodies used for flow cytometry 
Fluorochrome Antigen Clone Supplier 
-- CD16/32 93 BioLegend, San Diego, CA, USA 
APC 
CD25 PC61.5 eBioscience, San Diego, CA, USA 
CD80 1G10 Molecular Probes, OR, USA 
CD64 X54-5/7.1 
BioLegend, San Diego, CA, USA 
IFNγ XMG1.2 
IL17 TC11-18H10.1 
APC-Cy7 
CD19 6D5 
CD45 30-F11 
CD86 GL-1 
PE 
CD4 RM4-5 BD Biosciences, Franklin Lakes NJ, USA 
FoxP3 FJK-16s eBioscience, San Diego, CA, USA 
CD11c N418 
 
BioLegend, San Diego, CA, USA 
F4/80 BM8 
IL10 Jess-16E3 
Pe-Cy7 
CD3 145-2C11 
CD11b M1/70 
IFNγ XMG1.2 
IL17 eBio17B7 eBioscience, San Diego, CA, USA 
PerCP 
CD4 RMG1.2 BD Biosciences, Franklin Lakes NJ, USA 
CD19 ID3 
BioLegend, San Diego, CA, USA 
CD45 30F11 
FITC 
CD19 eBio1D3 eBioscience, San Diego, CA, USA 
MHCII M5/114.15.2 
BioLegend, San Diego, CA, USA 
Vα3.2 RR3-16 
BV421 
CD3 145-2C11 
CD11c N418 
NK1.1 PK136 
BV510 
 
CD8 53-6.7 
CD19 6D5 
CD69 H1.2F3 
MHCII M5/114.15.2 
Table 12. Fluorophore tagged monoclonal antibodies used for flow cytometry. All antibodies were 
diluted 1:200 in FACS buffer; except for the anti-CD16/CD32 (Fc Block), which was diluted 1:100 and 
used in all FACS stainings to avoid nonspecific binding.  
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2.1.12 Consumable material 
Consumable Supplier 
Bottle top filter, 0.2 µm Sarstedt, Nümbrecht, Germany 
BRAND seripettor pro bottle-top dispenser, 
10 ml 
Merck KGaA, Darmstadt, Germany 
Butterfly Winged Infusion Set (25G) Hospira UK Ltd, UK 
Cell culture flask, 75 cm2 Greiner bio-one, Kremsmuenster, Austria  
Cell culture plates, flat bottom (6 well, 24 
well, 96 well) 
Greiner bio-one, Kremsmuenster, Austria  
Cell strainer (70 µm, 40 µm) BD Biosciences, Franklin Lakes, NJ, USA 
Cryogenic tubes Thermo Scientific, Waltham, MA, USA 
FACS tubes (5 ml BD Biosciences, Franklin Lakes, NJ, USA 
Feather disposable scalpel (No. 11, No. 21) PFM medical AG, Köln, Germany 
GEM Scientific Razor Blades Alpha Biotech Ltd., Glasgow, UK 
LS columns for MACS separation Miltenyi Biotec, Bergisch Gladbach, Germany 
Needles (18G, 23G) BD Biosciences, Franklin Lakes, NJ, USA 
Nunc MaxiSorp 96 well ELISA plate Thermo Scientific, Waltham, MA, USA 
Nunc MicroWell Plates, round bottom 96 well 
plate 
Thermo Scientific, Waltham, MA, USA 
StatMatic II 8 channel Microplate Washer 
Gardner Denver Thomas GmbH, Fürstenfeldbruck, 
Germany 
Syringes (1 ml, 5 ml, 10 ml, 20 ml) BD Biosciences, Franklin Lakes, NJ, USA 
Tubes (50 ml, 10 ml, 2 ml, 1,5 ml, 0.2 ml) Sarstedt, Nuembrecht, Germany 
Table 13. Laboratory consumables. Abbreviations: ELISA: enzyme-linked immunosorbent assay; 
FACS: fluorescence-activated cell sorting; G: gauge. 
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2.1.13 Technical devices 
Devices Supplier 
Beurer IL11 Infrared Lamp Beurer GmbH, Ulm, Germany 
Centrifuge 5415 R Eppendorf, Hamburg, Germany 
Centrifuge 5810 R Eppendorf, Hamburg, Germany 
Excelsior AS automated tissue processor Life Technologies GmbH, Darmstadt, Germany 
FACS Canto II BD Biosciences, Franklin Lakes, NJ, USA 
Fluorescence/light microscope, Olympus BX51, 
equipped with DP71 digital and XM10 
monochrome camera 
Olympus, Hamburg, Germany 
Hera cell 150 incubator Heraeus, Hanau, Germany 
iQ5 Real Time PCR Detection System Bio-Rad, Munich, Germany 
iMark microplate reader Bio-Rad, Munich, Germany 
Leica SM2000 R sliding microtome Leica Biosystems Newcastle Ltd., UK 
MEDITE TES Valida paraffin embedding system MEDITE GmbH, Burgdorf, Germany 
Neubauer chamber 
Superior Marienfeld, Lauda-Koenigshofen, 
Germany 
Power Pac 300 Bio-Rad, Munich, Germany 
QuadroMACS separator Miltenyi Biotec, Bergisch Gladbach, Germany 
Thermocycler Biometra TRIO, Jena, Germany 
Thermomixer comfort UV Eppendorf, Hamburg, Germany 
UV transluminator Vilber Lourmat, Eberhardzell, Germany 
Table 14. Technical devices and special equipment.  
 
2.1.14 Software  
Software Application Supplier 
BD FACS Diva 
Software 6.1.2  
Flow cytometry data 
acquisition and analysis 
BD Biosciences, Franklin Lakes, NJ, USA 
FlowJo 7.6.1  Flow cytometry data analysis Tree Star Inc., Ashland, OR, USA 
GraphPad Prism 6 Statistical analysis  GraphPad software Inc., La Jolla, CA, USA 
Table 15. List of software used for data acquisition and analysis. 
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2.2 Transgenic mouse models 
All transgenic mice were housed at the animal facility of the University Medical Center 
Göttingen (UMG) under specific pathogen free (SPF) conditions. Animals were exposed to 
constant 12h/12h dark/light cycles and supplied with food and water ad libitum. All mice 
transported from outside the animal facility or to a new room (inside the bioterium) received 
one week of acclimation before the experiment started.  
Animal experiments were performed in agreement with the European Communities 
Council Directive of 24 November 1986 (86/EEC) and were approved by the Government of 
Lower Saxony, Germany. All genetically modified mice used for breeding, in vivo and ex vivo 
experiments are summarized in tables 16 and 17. 
2.2.1 C57Bl/6J mice 
6-8 weeks old female C57Bl/6J mice were purchased from Charles River laboratories, Sulzfeld, 
Germany or from the animal facility of the University Medical Center Göttingen. 
2.2.2 2D2 mice 
MOG specific T cell receptor (TCR) transgenic mice, which are also known as TCRMOG. Bettelli 
and colleagues developed the transgenic mouse model by using a CD4+ MOG35-55 specific T 
cell clone called 2D2, which expresses a TCR conformed by a Vα3.2 and Vβ11 chains. 
Approximately 30% of the 2D2 mice spontaneously develop optic neuritis without showing 
clinical or histological signs of EAE. 2-4% of the mice develop spontaneous EAE. 
2.2.3 Th/+ mice 
Knock in mice also referred as IgHMOG, were developed by Litzenburger and collaborators by 
inserting a transgenic IgH chain variable gene of the 8.18C5 MOG specific monoclonal 
antibody. Around 30% of all B cells in bone marrow and periphery are MOG specific. 
Consequently, high titers of MOG specific IgM antibodies are present in the sera of these mice. 
In contrast to 2D2 mice, the Th/+ transgenic mouse line does not spontaneously develop EAE. 
Upon active immunization or the adoptive transfer of MOG specific T cells, MOG specific 
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antibodies are switched to IgG1 and IgG2a isotypes leading to an earlier disease onset, 
increased EAE incidence and severity compared to non-transgenic animals252. 
2.2.4 OSE mice 
Krishnamoorthy and colleagues generated a double transgenic mouse model that 
spontaneously develops CNS demyelinating disease. They were named OSE or opticospinal 
EAE mice because the CNS lesions are located almost exclusively in the optic nerve and spinal 
cord. The mouse strain was generated by crossing the previously described 2D2 mice with 
Th/Th+ double transgenic mice on a C57BL/6 background. As a result, 50% of these mice 
express both, MOG specific T and B cells. OSE mice develop spontaneous EAE under specific 
pathogen free (SPF) conditions with a frequency of 30-50% depending on the animal facility101.  
Mouse 
model 
Expression method Developer / Reference 
Donating 
researcher 
2D2 
Transgene insertion: Vα3.2Jα18 
region of TCRa and Vβ11DJβ1,1 
region of TCRb from the 2D2 T 
cell clone inserted into TCR 
expression cassettes 
Esther Bettelli, Brigham and 
Women’s Hospital and 
Harvard Medical School253 
Generous gift 
from the group of 
Prof. Vijay K. 
Kuchroo, Harvard 
Medical School 
Th/Th+ 
Targeted insertion of  the 
rearranged VDJ gene of the H 
chain from the MOG specific 
hybridoma 8.18-C5 
Tobias Litzenburger, Max 
Plank Institute of 
Neurobiology252 
Generous gift 
from the group of 
Prof. Hartmut 
Wekerle 
OSE 
Double transgenic mice (derived 
from 2D2 and Th/+ mice 
breeding) 
Gurumoorthy Krishnamoorthy, 
Max Plank Institute of 
Neurobiology101 
Crossbreeding 
Table 16. Transgenic mouse models used for breeding, in vivo and in vitro experiments. 
Abbreviations: OSE: opticospinal EAE. 
2.3 Breedings 
All transgenic mice were generated from in-house breeding colonies at the UMG animal facility 
and backcrossed to C57BL/6 for more than 12 generations. Animals were mated between 6 
and 8 weeks of age.  
  
31 Methods 
2.3.1 Cell specific AhR KO mouse strains 
To examine the repercussions of AhR signaling in certain immune players, a variety of cell 
specific Cre lines (CD11cCre, FoxP3Cre, GFAPCre and CD4Cre) were crossed to AhRfl/fl mice 
(table 17) to specifically delete AhR in DC, Tregs, astrocytes and CD4+ T cells. The generated 
AhRDC, AhRTreg, AhRAstro and AhRCD4 mice were used in the context of actively induced 
EAE, by immunization with MOG35-55 and CFA as described in 2.4.2.  
On the other hand, the same transgenic lines were bred to 2D2 and Th/Th+ mice to 
obtain: OSE AhRfl/fl, OSE AhRCD4, OSE AhRTreg, OSE AhRAstro and OSE AhRDC. Using the 
breeding strategy depicted in figure 2, the repercussions of a cell specific AhR deletion on a 
spontaneous EAE model were studied.  
Figure 2. Breeding strategy used to produce four different cell specific AhR KO mouse strains 
that develop spontaneous EAE. The different strains are double transgenic (opticospinal or OSE) mice 
generated by crossing 2D2 and Th/Th+ animals: OSE AhRCD4, OSE AhRTreg, OSE AhRAstro and OSE 
AhRDC. Taking advantage of the Cre/Lox system, cell specific AhR KO were produced by breeding 
AhRfl/fl mice with animals expressing an active Cre recombinase controlled by a defined promoter 
(CD4Cre, FoxP3Cre, GFAPCre and CD11cCre).  
 
 To further characterize the APCs compartment of the OSE mice, reporter animals 
expressing an enhanced green fluorescent protein (EGFP) under the control of a CX3CR1 
promoter were bred to the OSE AhRDC or OSE AhRfl/fl control littermates generating OSE 
AhRDC CX3CR1EGFP/+ and OSE AhRfl/fl CX3CR1EGFP/+ control mice. 
2.3.2 AhRfl/+ CD11cCre+ R26eYFP mice (CD11c specific AhR KO) 
To investigate AhR deletion in CD11c+ DC cells, AhR competent (AhR+/+) or AhR KO (AhR-/-) 
CD11cCre mice were bred with AhRfl/fl animals to generate AhRfl/+ CD11cCre+ controls and AhRfl/- 
CD11cCre+ offspring. The CD11cCre+ transgenic mice are described in table 17 and harbor Cre 
recombinase under the control of a CD11c promoter254.  
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The AhRfl/fl animals were previously crossed to R26eYFP transgenic mice carrying an 
enhanced yellow fluorescent protein (eYFP) inserted into the Gt(ROSA)26Sor locus and 
blocked by an upstream loxP flanked STOP sequence255. The breeding of AhRfl/fl R26eYFP 
animals with AhR+/- CD11cCre+ led to the deletion of the AhR targeted gene in one allele of 
CD11c+ cells. Cre recombinase activation deleted the STOP sequence in CD11c+ cells and 
was reported by eYFP expression. 
 The generated mice (AhRfl/+ CD11cCre+ R26eYFP and AhRfl/- CD11cCre+ R26eYFP) offered 
the advantage that eYFP+ AhR competent or AhR deficient DC can be sorted ex vivo for further 
analysis and its generation is depicted in figure 3. 
 
Figure 3. Breeding strategy used to generate AhRfl/+ CD11cCre+ R26eYFP and AhRfl/- CD11cCre+ 
R26eYFP control mice. The transgenic animals carry a Cre recombinase active under the control of a 
CD11c promoter and a Cre dependent eYFP reporter gene that labels CD11c+ cells upon Cre 
recombinase activation. AhRfl/- CD11cCre+ R26eYFP lack AhR in DC cells and AhRfl/+ CD11cCre+ R26eYFP 
are AhR+/- in CD11c+ cells. 
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2.3.3 CD11ctdTomato CX3CR1eGFP transgenic line 
To evaluate the different intestinal APCs populations CX3CR1eGFP mice were bred with the 
CD11cCre and R26tdTomato transgenic strains. The R26tdTomato mice harbor a loxP flanked STOP 
cassette designed to prevent transcription of the red fluorescent protein variant. When they 
were bred to the CD11cCre mice that express Cre recombinase under the control of a CD11c 
promoter, the resulting offspring deleted the STOP cassette in CD11c+ cells marking them with 
tdTomato fluorescence. Because this CAG promoter driven reporter construct is inserted into 
the Gt(ROSA)26Sor locus, robust tdTomato expression is determined by the CD11c Cre 
recombinase.  
 
Target gene Expression method Developer / Reference Supplier 
AhRtm1 Targeted (knock out) 
Christopher A Bradfield, University 
of Wisconsin-Madison149 
Jackson 
Laboratory 
AhRtm1.2 Targeted (knock out) 
Taconic in collaboration with CXR 
Biosciences 
Taconic 
AhRtm3.1Bra/ 
AhRfl/fl 
Targeted mutation 3.1 
(floxed) 
Christopher A Bradfield, University 
of Wisconsin-Madison256 
Jackson 
Laboratory 
CD11cCre  
Transgenic 
(Recombinase 
expressing) 
Boris Reizis, Columbia University 
Medical Center254 
CD4Cre 
Transgenic insertion 1 
(Recombinase 
expressing) 
Christopher B. Wilson, University 
of Washington257,258 
CX3CR1EGFP/+ 
Transgene insertion 
4097, (Recombinase 
expressing) 
Dr. Dan R. Littman, New York 
University Medical Center259 
FoxP3YFP Cre 
Targeted mutation 4, 
(Recombinase 
expressing) 
Alexander Rudensky, Memorial 
Sloan Kettering Cancer Center260 
GFAPCre 
Transgene insertion 
73.12, (Recombinase 
expressing) 
Michael V Sofroniew, University of 
California Los Angeles261 
Charles River 
Laboratories, 
Sulzfeld, 
Germany. 
R26tdTomato 
Targeted mutation 9 
 
Hongkui Zeng, Allen Institute for 
Brain Science262 Jackson 
Laboratory 
R26eYFP 
Targeted mutation 1 
(eYFP reporter gene) 
Frank Costantini, Columbia 
University Medical Center255 
Table 17. Transgenic mouse lines used to generate AhR specific knock out mice through the 
Cre/Lox system. Abbreviations: CX3CR1: chemokine receptor 1; EGFP: enhanced green fluorescent 
protein; FoxP3: forkhead box P3; GFAP: glial fibrillary acidic protein; Itgax: integrin alpha X; TM: targeted 
mutation; R26: rosa 26 locus; YFP: yellow fluorescence protein. 
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2.4 Methods 
2.4.1 Genotyping of transgenic mice 
PCR based genotyping of all transgenic mouse lines was performed by Ms. Katja Schulz 
(Department of Neuropathology, University Medical Center Göttingen). 
2.4.1.1 DNA extraction 
Genomic DNA was isolated from tail biopsies of AhRfl/fl, AhRCD4, AhRTreg, AhRAstro and 
AhRDC, 2D2, Th/+, OSE AhRfl/fl, OSE AhRCD4, OSE AhRTreg, OSE AhRAstro, OSE AhRDC, 
OSE AhRDC CX3CR1EGFP/+ and OSE AhRfl/fl CX3CR1EGFP/+ mice at 3 weeks of age.  
In order to isolate genomic DNA, the tails were digested using a mixture of 20 µl Proteinase 
K and 350 µl tail lysis buffer in a thermomixer at 350 rpm and 56°C overnight. Samples were 
centrifuged for 5 min at 13200 rpm and the supernatants were collected into new tubes. Each 
tube received 350 µl of isopropyl alcohol to precipitate the DNA.  
All samples were carefully mixed, centrifuged and the supernatants were discarded. 
Subsequently, 350 µl of 70% ethanol were added before the last centrifugation step. The DNA 
pellet was dried for 10-15 min at 45°C in a speed vacuum concentrator and resuspended in 
100 μl bidistilled H2O. 
2.4.1.2 Polymerase chain reaction (PCR) 
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Buffer 4 4 4 4 2,5 4 4 4 
dNTPs 0.4 0.4 1 1 0.15 0.5 0.4 1 
Primers 
0.5 
each 
0.5 
each 
1 
each 
0.5 
each 
0.25 
each 
0.5 
each 
0.5 
each 
0.5 
each 
DNA 
polymerase 
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Bidistilled H2O 9.5 9.4 7.9 7 8.9 8.9 9.4 8.4 
Genomic DNA 2 2 2 2 2 2 2 2 
MgCl2 (25mM) -- -- -- 1 0.5 0.5 -- -- 
Table 18. Composition of PCR reactions used for transgenic mice genotyping. A mixture of Go-
Taq DNA polymerase buffer (5x), deoxynucleotide triphosphates (dNTPs), reverse and forward primers, 
Go-Taq DNA polymerase, bidistilled H2O and genomic DNA was used for all reactions. Primers were 
used at a concentration of 10mM; except for GFAP (100 pmol) and dNTPs at concentration of 2,5 mM; 
except for FoxP3 and GFAP (10 mM). All quantities are given in microliters (µl).  
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The PCR reaction components are listed on table 18 for each of the transgenic mouse 
lines and all primers are described in table 7. PCR reactions were run in a T3 thermocycler 
and the specific cycling conditions are described in table 19. Ethidium bromide stained PCR 
products were separated by electrophoresis on agarose gel at 120 volts for 60-90 minutes and 
the product length was evaluated using a 100 base pairs (bp) DNA ladder under UV light. 
Step 2D2 AhRfl/fl CD11cCre CD4Cre 
 °C time  °C time  °C time  °C time  
1. Pre-
denaturation 
95 2 m  94 3 m  94 3 m  94 3 m  
2. Denaturation 95 1 m 
30 
cycles 
94 30 s 
35 
cycles 
94 30 s 
35 
cycles 
94 30 s 
35 
cycles 
3. Annealing 58 1 m 60 20 s 60 1 m 51,7 1 m 
4. Elongation 72 1 m 72 20 s 72 1 m 72 1 m 
5. Final 
elongation 
72 
10 
m 
 72 2 m  72 2 m  72 2 m  
6. Storage 10 hold  10 hold  10 hold  10 hold  
Product size 
(bp) 
Transgene: ~700 
WT: 106 
Homozygous:140 
Heterozygous: 
106 + 140 
Transgene: ~313 Transgene: ~100 
Step GFAPCre FoxP3Cre Th/+ CX3CR1EGFP/+ 
 °C time  °C time  °C time  °C time  
1. Pre-
denaturation 
98,5 3 m  94 2 m  95 2 m  94 3 m  
2. Denaturation 98,5 30 s 
35 
cycles 
94 30 s 
28 
cycles 
95 1 m 
30 
cycles 
94 30 s 
35 
cycles 
3. Annealing 65 45 s 61 20 s 61 1 m 60 30 s 
4. Elongation 72 1 m 72 20 s 72 1 m 72 1 m 
5. Final 
elongation 
72 2 m  72 2 m  72 
10 
m 
 72 
10 
m 
 
6. Storage 10 hold  10 hold  10 hold  10 hold  
Product size 
(bp) 
Transgene: ~100 
WT: 322 
Homozygous:346 
Heterozygous: 
322 + 346 
WT: 150 
Homozygous:100 
Heterozygous: 
150 + 100 
WT: 400 
Homozygous: 800 
Heterozygous: 400 
+ 800 
Table 19. 6 step PCR programs used in the T3 thermocycler for transgenic mice genotyping. 
Abbreviations: m: minutes; s: seconds. 
For the genotyping of AhRfl/fl, AhRCD4, AhRTreg, AhRAstro and AhRDC two PCR 
reactions were performed: one for the AhRfl/fl, gene and one for the corresponding Cre 
transgene under control of a CD11c, CD4, FoxP3 or GFAP promoter. For the OSE AhR∆DC, 
OSE AhRCD4, OSE AhRTreg, OSE AhRAstro and OSE AhRfl/fl CX3CR1EGFP/+ two additional 
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reactions were performed one to detect the Vα3.2Jα18 TCR gene (2D2 mice) and one for the 
Igh-J gene (Th/+ mice). 
2.4.2 Mouse immunization with MOG35-55 and EAE induction 
AhRDC, AhRTreg, AhRAstro, AhRCD4 and AhRfl/fl control mice were actively immunized with a 
subcutaneous (s.c.) injection of 50 µl of MOG35-55 emulsified in complete Freund’s adjuvant 
(CFA, composition detailed in table 3) per groin and per axilla (200 µg MOG35-55/animal). The 
s.c. inoculation was accompanied by an intraperitoneal (i.p.) injection of 400 ng of pertussis 
toxin (PTX) on the day of immunization and two days later.  
2.4.3 Clinical EAE score 
All animals were observed after immunization and scored daily based on a scale of disease 
severity. The scale ranges from 0 (healthy) to 5 (death) as shown in table 20.  Ethical standards 
dictate that animals reaching 3.5 should be immediately sacrificed. The animals that died 
because of EAE were scored 5 and the ones sacrificed for ethical reasons were documented 
with the last given score until the experiment ended. 
Score Clinical signs Description 
0 Healthy No neurological deficits 
0.5 Partially limp tail The distal part of the tail is weak or paralyzed 
1 Tail paralysis The complete tail is flaccid and hanging loosely 
2 
Impair righting reflex, hind 
limbs weakness 
Positive flip test: The mouse struggles to roll back onto its 
feet when laid on its back 
2.5 
1 or 2 hind limbs 
incomplete paralysis 
Hind limbs are unsteady producing wobbling when walking 
3 
Hind limbs complete 
paralysis 
Front paws are very active for grasping. The mouse can 
easily support its own weight using only the fore paws. 
3.5 
Hind limbs and abdomen 
paralysis 
The mouse lacks the strength to hang on the grid and it is not 
able to reach the water bottle and food located on the lid. 
4 Fore limbs weakness Inactive behavior, loss of muscular tone of all limbs 
4.5 Moribund 
The paralysis extends to the fore limbs, altered breathing and 
usually prostrated. 
5 Dead  
Table 20. Scoring scale for EAE clinical monitoring. Detailed description of the clinical signs that 
characterized each stage of disease severity according to the followed EAE scale. 
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2.4.4 Laquinimod administration  
Laquinimod was dissolved in water and administered daily to the mice by oral gavage at a 
dosage of 25 mg/kgbody weight for MOG immunized mice and 50 mg/kgbody weight for animals 
transferred with B16F10 melanoma cells. Every week the animals were weighted and the 
dosages were adjusted accordingly. The control animals received the same volume of tap 
water. Laquinimod was a generously provided by Teva Pharmaceutical Industries, Ltd., 
Netanya, Israel.  
Laquinimod treatment was started on the day of immunization and continued daily for 
10 days if immunological analyses were performed or for 30 days to follow the clinical disease 
course. 
2.4.5 Preparation of single cell suspensions from the spleen for ex vivo analysis 
Laquinimod or vehicle treated animals were sacrificed by cervical dislocation after anesthesia. 
Spleens were dissected and transferred into a 10 ml tube with cold RPMIcomplete. This procedure 
was performed under the hood for the sterile acquisition of splenocytes. Unless stated 
otherwise, cells were washed with 10 ml of cold RPMIcomplete and centrifuged for 10 minutes at 
300 x g and 4°C. 
Mechanical dissociation was used to disrupt the spleens, which were pressed through 
a 70 µm strainer using the plunger end of a syringe. The remaining cells were washed through 
the strainer, collected into 50 ml tubes and centrifuged. The pellet was resuspended in 1 ml of 
BD Pharm lyse solution (1:10 diluted in bidistilled H2O) and incubated for 3 min at 37°C to lyse 
erythrocytes. The reaction was stopped by adding 20 ml of cold RPMIcomplete and the cells were 
washed twice. 
2.4.6 Cell counting with Neubauer chamber 
Before being plated for FACS staining, the cells were stained with trypan blue to test cell 
viability and counted in a Neubauer chamber. Living cells with intact cell membranes exclude 
dyes such as trypan blue allowing us to differentiate between dead and viable cells.  
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Therefore, 10 µl of the cell suspension were diluted 1:10 in trypan blue (previously 
diluted 1:10 in PBS) and transferred to the capillary gap between the chamber bottom and the 
cover glass. The cell concentration was determined by counting the number of cells in the four 
outer squares of 1 mm2 of area and 1 µl of volume using the 10x objective of the light 
microscope.  
The concentration of cells was then calculated according to the following formula: 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑐𝑒𝑙𝑙𝑠/𝑚𝑙)  =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 × 10 000
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛
 
2.4.7 Isolation of lymphocytes from the small intestine 
6 to 8 weeks old OSE AhRDC, OSE AhRfl/fl, OSE AhRDC CX3CR1EGFP/+ and OSE AhRfl/fl 
CX3CR1EGFP/+ animals were used to isolate lymphocytes from the gut. The small intestine was 
dissected leaving approximately 0.5 cm separation below the stomach and 0.5 cm above the 
caecum, transferred to a Petri dish with cold PBS and cut in ~5 cm long pieces. Each segment 
was cleaned from the remaining connective tissue, fat and blood vessels. The faeces were 
rinsed from the intestine pieces using a 10 ml syringe filled with cold PBS and 18G needle. 
The intestinal lumen was flushed with approximately 40 ml per mouse or until no remaining 
fecal matter was observed. 
2.4.7.1 Isolation of lymphocytes from the Peyer patches 
5 to 10 Peyer’s patches (PP) per mouse were removed from the intestines of each mouse 
using small scissors and curved tweezers to hold tight these structures. After excision, all PP 
were transferred into a 50 ml tube with cold RPMIcomplete and remained on ice until further 
treatment. The content of the tube with the PP was filtered through a 70 µm strainer and the 
tissue was disrupted by mechanical dissociation using the plunger of a 5ml syringe. The 
strainer was flushed with 10 ml cold RPMIcomplete.  
2.4.7.2 Isolation of intraepithelial lymphocytes 
After removing the PP, the intestine segments were opened longitudinally and further cut in 
0.5 cm pieces. The sections obtained were washed 3 times with cold PBS using a metallic 
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sieve and transferred into a 50 ml tube with 10 ml prewarmed predigestion solution. This buffer 
contains EDTA (cation chelant) and DTT (reducing agent), which have been shown to increase 
intestinal intraepithelial lymphocytes (IEL) isolation purity263. 
 The tissue was vigorously mixed using a tube rotator at maximum speed for 10 to 15 
minutes at 37°C and vortexed for 15 seconds. Subsequently, the 10 ml content containing 
detached IEL was filtered through a 70 µm strainer and collected into a 50 ml tube. The strainer 
was rinsed with 5 ml cold PBS and the tissue was transferred into a new tube with fresh 15 ml 
prewarmed predigestion solution. The tube was placed again inside the warming chamber and 
the same procedure was repeated 3 times until collecting a final volume of 45 ml IEL 
suspension.  
2.4.7.3 Isolation of lamina propria lymphocytes 
The remaining predigested tissue was washed 3 times with cold PBS, cut into smaller pieces 
and transferred into a 50 ml tube with 5 ml prewarmed digestion solution. The dissociation 
buffer contains collagenase D and DNase I for enzymatic degradation of the connective tissue 
forming the lamina propria (LP) underneath the intestinal epithelium.  
Samples were mixed using a rocking platform at 190 rpm for 15 to 20 minutes at 37°C,  
and vortexed for 20 seconds. The 5 ml content was filtered through a 40 µm strainer and 
collected into a 50 ml tube. 5 ml of cold RPMIcomplete were used to rinse the strainer. Next, the 
tissue was transferred into a new tube with fresh 5 ml prewarmed digestion solution and placed 
again on the rocking platform. The same procedure was repeated 4 times, generating a final 
volume of 40 ml containing the isolated lamina propria lymphocytes (LPL). 
Cells obtained from OSE AhRDC CX3CR1EGFP/+ and OSE AhRfl/fl CX3CR1EGFP/+ animals 
were always protected from light exposure. During incubation periods the cells always 
remained on ice and centrifugations ran for 10 minutes at 400 x g at 4°C if not stated differently. 
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2.4.7.4 Separation of lymphocytes using a Percoll gradient  
The IEL and LPL obtained from the predigestion and digestion steps were centrifuged and 
resuspended in 10 ml DMEMhigh-Glu. After an additional centrifugation, cells were resuspended 
in 8 ml master mix (40% Percoll solution), thoroughly mixed and gently added onto 5 ml of 80% 
Percoll solution, which was previously poured into a 15 ml tube as shown in figure 4. The tubes 
containing 40 and 80% Percoll phases corresponding to either IEL or LPL (2 per mouse) were 
centrifuged for 25 minutes at 400 x g at 20°C without break and deceleration. 
 
Figure 4. Schematic representation of the tubes containing 40 and 80% Percoll phases before 
and after the Percoll gradient centrifugation. This procedure was used to separate either 
intraepithelial or lamina propria lymphocytes from the small intestines. 
 
After the Percoll gradient centrifugation, a fraction of the 40% Percoll upper layer was 
removed using a glass pipette connected to a vacuum pump in order to have better access to 
the layer beneath comprising the intestinal lymphocytes. Using a 1 ml micropipette, the 
intestinal lymphocytes from the Percoll interphase were transferred into a new tube containing 
10 ml of FACS buffer.  
The 3 tubes obtained from each mouse (containing IEL, PP and LP lymphocytes) were 
centrifuged and resuspended in FACS buffer. Cells were counted as described in section 2.4.6 
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and plated in 96 well plates (500 000 cells per well) before proceeding to extra and intracellular 
FACS stainings. 
2.4.8 Flow cytometry staining and analysis 
Once the cell concentration was determined, single cell suspensions were transferred to round 
bottom 96 well plates (0.5-1 x 106 cells per well), centrifuged and washed twice. Unless stated 
otherwise, cells were washed with 200 µl of cold FACS buffer per well and centrifuged for 10 
minutes at 300 x g and 4°C.  
2.4.8.1 Detection of extracellular proteins  
For extracellular FACS stainings a master mix was prepared beforehand with 8 fluorochrome 
labeled antibodies diluted 1:200 and BD Fc block (anti-CD16/CD32) diluted 1:100 in FACS 
buffer (table 12). 50 µl of staining solution was added per well. Cells were incubated with the 
master mix in the dark for 12 minutes at 4°C, centrifuged and washed twice.  
2.4.8.2 Intracellular detection of FoxP3  
Intracellular detection of the transcription factor FoxP3 was performed after staining all surface 
molecules as described in the previous section. Subsequently, cells were incubated and fixed 
in FoxP3 fixation concentrate diluted 1:4 in the dilution buffer for 1 hour. After centrifugation, 
cells were washed twice with FoxP3 permeabilization buffer diluted 1:10 in bidistilled H2O. After 
centrifugation, cells were resuspended with the anti-FoxP3 antibody diluted 1:100 in 
permeabilization buffer and incubated for 30 minutes at 4°C in darkness. Next, 100 µl of 
staining solution were added per well. Cell suspensions were centrifuged and washed twice. 
2.4.8.3 Intracellular detection of IFNγ and IL17 
Ionomycin is a calcium ionophore and PMA is a small organic compound that freely diffuses 
through the cell membrane. They stimulate cytokine secretion by activating calcium release 
and protein kinase C (PKC) signaling, respectively264–267. In order to quantify CD4+ T cell 
production of IFNγ and IL17 and before proceeding to the staining protocol, cells were 
stimulated with 25 ng/ml phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml ionomycin in 
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RPMIcomplete for at least 6 hours at 37°C and 5% CO2 in round bottom 96 well plates. After the 
first hour of incubation, cytokine secretion was blocked adding Golgi Stop protein transport 
inhibitor (monensin) 1:1000 to the medium.  
After stimulation with PMA and ionomycin, cell surface molecules were detected as 
described in section 2.4.8.1 and using FACS buffer with Golgi Stop diluted 1:1000. All FACS 
extra and intracellular stainings were performed under the hood in sterile conditions to avoid 
contamination of the stock antibodies.  
For intracellular staining of cytokines, cell suspensions were fixed with 
Cytofix/Cytoperm for 1 hour, washed twice with Perm/Wash buffer diluted 1:10 in bidistilled 
H2O and incubated with anti-IL17 and anti-IFNγ antibodies diluted 1:50 in Perm/Wash buffer 
in the dark for 30 minutes at 4°C. 50 µl of staining solution was added per well.  
2.4.8.4 Flow cytometry analysis 
Cell suspensions were centrifuged and washed twice. Flow cytometry analysis was 
performed using a FACS Canto II device able to detect an eight color panel using FITC, PE, 
PerCP-Cy5.5, PE-Cy7, APC, APC-Cy7, AmCyan, and Pacific Blue fluorophores. Different 
combinations of the eight fluorophore labeled antibodies (listed in table 12) were used for 
FACS stainings. BD FACSDiva Software 6.1.2 was used to preview and record data from all 
samples. 
2.4.9 Histology 
2.4.9.1 Preparation of mouse tissue for immunohistochemistry 
CD11ctdTomato, CX3CR1eGFP and double transgenic CD11ctdTomato CX3CR1eGFP mice were 
sacrificed by cervical dislocation after anesthesia and transcardially perfused with PBS. Small 
intestines were dissected leaving approximately 0.5 cm separation below the stomach as 
described in section 2.4.7. The mesenteric fat and blood vessels were carefully removed and 
the intestinal content was flushed with cold PBS using a 10 ml syringe and 18G needle. 
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The small intestine samples were fixed overnight in 4% PFA and incubated 1 day in 
PBS, loaded in cassettes, dehydrated and immersed in paraffin using an Excelsior AS 
automated tissue processor. Tissues were embedded in paraffin blocks using a MEDITE TES 
Valida paraffin embedding system and cut in 2 to 4 µm sections using a Leica SM2000 R 
sliding microtome. 
2.4.9.2 Deparaffinization and dehydration of small intestine sections 
Before further immunohistochemistry methods, all sections were heated in an oven at paraffin 
melting point (56-58°C) for at least 1 hour, gradually deparaffinized in xylene and rehydrated 
in graded isopropyl alcohol series as shown in table 21.  
Reagent Repetitions Function 
Xylene 4 x 5 minutes 
Deparaffinization 
Isopropyl alcohol/Xylene 1 x 2 minutes 
Isopropyl alcohol (100%) 2 x 3 minutes 
Rehydration 
Isopropyl alcohol (90%) 1 x 3 minutes 
Isopropyl alcohol (70%) 1 x 3 minutes 
Isopropyl alcohol (50%) 1 x 3 minutes 
Distilled water to rinse 30 seconds 
Table 21. Deparaffinization and rehydration series of paraffin embedded sections. Before 
proceeding to any immunostaining protocol all slides were deparaffinized and rehydrated.  
 
2.4.9.3 Fluorescent immunohistochemistry  
CD11ctdTomato CX3CR1eGFP transgenic mice were used to visualize CD11c+ and CX3CR1+ cells 
in the small intestines. To enhance the fluorescence intensity, immunohistochemistry with anti-
GFP and anti-RFP antibodies was performed. 
To avoid antigen masking after PFA fixation, citrate buffer antigen retrieval was 
performed before the immunohistochemical staining268,269. The citrate based solution is 
designed to break the protein cross-links, hence unmask the antigens and epitopes in paraffin 
embedded tissue sections, enhancing the intensity of antibodies.  
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The sections were incubated in preheated sodium citrate buffer 10 mM, pH=6 in a 
steamer at 95-100°C for 30 minutes. If not stated otherwise, the next part of the protocol was 
performed at room temperature and the washing steps were repeated 3 times for 5 minutes 
using PBS.  
After washing, the slides were incubated with 3% hydrogen peroxidase solution for 60 
minutes in order to block endogenous peroxidase activity, 1% triton for 20 minutes and 10% 
goat serum for 30 minutes to reduce nonspecific hydrophobic binding. Washing steps were 
performed between the incubations. 
All sections were washed and incubated overnight with a polyclonal anti-GFP primary 
antibody (#PABG1-100) diluted 1:2000 (table 10). To enhance the immunohistochemical 
detection of  eGFP, tyramide signal amplification was performed on paraffin embedded 
sections270 using the Tyramide SuperBoost Alexa Fluor 488 kit (table 4). This kit is based on 
the activation of Alexa Fluor tyramids by horseradish peroxidase (HRP), resulting in the 
formation of tyramide radicals that covalently bind to tyrosine residues in close proximity of the 
HRP. 
The Tyramide SuperBoost Alexa Fluor 488 kit was used according to the manufacturer 
instructions. Briefly, the next day the slides were washed and incubated with a biotinylated 
anti-rabbit IgG antibody (#111-065-144) diluted 1:500 (table 11) for 1 hour. After washing, the 
slides were developed in tyramide working solution and the reaction was monitored using a 
fluorescence microscope. After 10 minutes the reaction was stopped using the Reaction Stop 
Reagent.   
Subsequently, the slides were washed and incubated overnight with a polyclonal anti-
RFP antibody (#600-401-379S) diluted 1:100 (table 10) at 4°C. The next day, the sections 
were washed and stained with a Cy3 conjugated anti-rabbit IgG antibody (#111-165-144) 
diluted 1:100 (table 11) for 2 hours in darkness. 
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 After washing, nuclei were counterstained with DAPI (1:10 000 in PBS) for 10 minutes. 
Slides were washed again, rinsed once in distilled water and mounted using fluorescence 
mounting medium. 
2.4.10 CYP1A1 expression analysis  
In order to analyze expression of the AhR targeted gene CYP1A1, dendritic cells were isolated 
from the spleens of AhRfl/+ CD11cCre+ R26eYFP and AhRfl/- CD11cCre+ R26eYFP transgenic mice 
(depicted in figure 3). Single cell suspensions were prepared and counted using a Neubauer 
chamber as described in sections 2.4.5 and 2.4.6.  
2.4.10.1 Purification of dendritic cells  
Dendritic cells were purified by depletion of non-target cells (negative selection) using 
magnetic activated cell sorting (MACS). Single cell suspensions were centrifuged for 10 
minutes at 300 x g and 4°C and resuspended in 10 ml of MACS buffer. Cells were flushed 
through a 40 µm cell strainer and then rinsed with an equal volume of MACS buffer passed 
through the filter. 
 The Pan Dendritic Cell Isolation Kit (mouse), LS columns and the QuadroMACS 
separator were used according to the manufacturer’s instructions. After MACS separation, 
cells were resuspended in 200 µl of FACS buffer and YFP+ DC were further purified using a 
BD FACS Aria II cell sorter.  
2.4.10.2 Quantitative real time PCR analysis of CYP1A1 expression  
AhR deficient (AhRfl/- CD11cCre+ R26eYFP) and AhR competent (AhRfl/+ CD11cCre+ R26eYFP) DC 
were cultured in round bottom 96 well plates at a concentration of 250 000 cells per well and 
were ex vivo stimulated with 250 nM of FICZ, high affinity agonist of AhR, for 24 hours. 
 After FICZ stimulation, the supernatant was removed and the DC were lysed in QIAzol 
Lysis Reagent. Subsequently, RNA was isolated using the NucleoSpin RNA XS Kit following 
the manufacturer’s protocol for cultured cells and transcribed into cDNA using the High‐
Capacity RNA‐to‐cDNA Kit according to the instructions provided. 
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Quantitative PCR was performed in the iQ5 Real Time PCR Detection System using 
the qPCR Core Kit obtained from Eurogentec. The following FAM labeled primers/probes 
(TaqMan Gene Expression Assays) were selected to be intron spanning from Life 
Technologies: GAPDH (Mm99999915 g1) and CYP1A1 (Mm00487218 m1). 
2.4.11 B16F10 melanoma cell culture and passaging 
B16F10 melanoma cells271,272 were cultured in 75 cm cell culture flasks using RPMIcomplete. 
Cultures were routinely split (1:10) every second to third day when confluence was reached. 
For cell passaging, the medium was discarded and non-adherent cells were removed by 
washing with 10 ml PBS before cell dissociation. 1.5 ml of prewarmed 0.01% trypsin solution 
in PBS was added and cells were incubated at 37°C for 5-7 minutes to ensure cell detachment.  
To inactivate the trypsin enzymatic action, 8.5 ml 10% FCS containing media 
(RPMIcomplete) were added to the flask. 1/10 of the cell suspension was transferred to a new 
flask with fresh RPMIcomplete and maintained in a humidified 37°C, 5% CO2 incubator until 
confluent growth and subsequent cell passage or until needed for i.v. inoculation. 
2.4.12 In vivo lung tumor model 
Low density melanoma cell cultures were used for i.v. transfer, which are known to efficiently 
form lung tumor colonies273. Approximately 50% confluent B16F10 melanoma cells were 
trypsinized as described in 2.4.11 and washed with 10 ml RPMIcomplete. Cells were counted with 
a Neubauer chamber as explained in section 2.4.6.  
B16F10 cells were resuspended in 0.5% EDTA in PBS and pipetted thoroughly before 
every injection to avoid cell clumping. Cell suspensions were i.v. injected into the lateral tail 
veins using 27G needles and 1 ml syringes. All animals were immobilized using a restrainer 
and the tail veins were dilated under an infrared lamp.  
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2.4.12.1 Preventive regimen 
C57BL/6 and AhR KO mice received Laquinimod 50 mg/kgbody weight or vehicle by oral gavage 
for 14 days. After 3 days of treatment animals were i.v. transferred with 0.5x106 B16F10 
melanoma cells. At day 11 after tumor inoculation the mice were sacrificed to obtain the lungs. 
2.4.12.2 Therapeutic regimen 
C57BL/6 were injected in the lateral tail vein with 0.2x106 B16F10 melanoma cells. Melanoma 
cells take 5-10 days to establish and form tumors274. Therefore, treatment with vehicle or 
Laquinimod 50 mg/kgbody weight was initiated at day 11 after i.v. injection once the melanoma 
cells have established in the lungs. After 1 week of treatment with Laquinimod or water (day 
19), all mice were sacrificed and the lungs were isolated.  
2.4.12.3 Lung isolation and metastasis quantification 
After following the preventive or therapeutic treatment the mice from all experimental groups 
were sacrificed by a lethal i.p. injection of 14% chloral hydrate. The lungs were carefully 
dissected, weighted, rinsed with cold PBS and fixed overnight in 4% PFA buffer. Samples were 
washed with PBS and the number of metastatic colonies were counted under the stereoscopic 
microscope with an ocular morphometric grid. 
2.4.13 Preparation of serum samples for MOG antibody quantification 
Blood samples were collected from WT, OSE AhRDC and OSE AhRfl/fl mice older than 100 
days. Mice were restrained using the scruffing technique and 100 to 200 µL of blood were 
drawn from the submandibular vein using a 23G needle. After collection, samples were allowed 
to clot and centrifuged at 300 x g for 10 minutes at 4°C. After centrifugation the resulting 
supernatant or serum was carefully transferred into a new tube. Serum samples were stored 
at -20°C until further use. 
Anti–MOG antibody titers were determined in the serum samples of OSE AhRDC and 
OSE AhRfl/fl mice by an enzyme-linked immunosorbent assay (ELISA). Sera obtained from WT 
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mice were used as a negative control. For this purpose, sterile 96 well ELISA plates were 
coated with 100 µl per well of MOG1-125 (8 µg/ml) diluted in PBS at 4°C overnight.  
The next part of the assay was performed at RT. If not stated otherwise, the washing 
steps were repeated 5 times by adding ELISA wash buffer with an 8 channel microplate washer 
connected to a top bottle dispenser. The plates were dried by tapping the inverted plates 
against paper towels. 250 µl of ELISA blocking buffer were added per well and incubated for 
2 hours. Plates were washed and 100 µl of the serum diluted in blocking buffer were added 
per well. 5-fold serum dilutions (1:500, 1:2500, 1:12500, 1:62500 and 1:312500) were 
incubated for 1.5 hours at RT.  
Once more blots were washed and 100 µl of polyclonal anti – mouse IgG1 and IgG2A 
HRP secondary antibodies (1:4000) were added per well and incubated 1 hour in the dark. 
The last washing step was repeated 7 times and 100 µl per well of TMB substrate premixed 
with hydrogen peroxide (H2O2) were added. The colorimetric reaction formed a soluble blue 
product obtained from the TMB oxidation in the presence of the HRP conjugates and H2O2. 
The reaction was stopped with 50 µl per well of ELISA stop solution to stabilize color 
development, which turns yellow upon addition. The optical density was measured at 450 nm 
with 540 nm wavelength as reference using the iMark microplate reader. Samples were run in 
triplicates used to calculate the average absorbance values at different dilutions and the 
average background OD was subtracted to each value. 
2.4.14 Indol-3-carbinol enriched diet regimen 
To investigate the effect of AhR ligands ingested in the diet using a spontaneous EAE model, 
OSE mice were submitted to a chemically defined diet (E1500) enriched or not with 2 mg/kg 
of indol-3-carbinol (I3C2mg/kg). At birth, all mothers of OSE mice received free access to the 
food corresponding to its experimental group. 
Animals were randomly assigned to either I3C enriched diet or control group and food was 
continuously provided. The spontaneous disease development was monitored for 100 days 
after birth.   
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3 .  RESULTS 
3.1 Physiological AhR ligands reduce spontaneous CNS autoimmunity by 
acting on dendritic cells 
Multiple endogenous and dietary ligands are known to activate AhR signaling in different 
immune compartments. An abundant source of indole – based AhR agonists can be found 
among members of the Brassica genus consumed in the diet; including broccoli, cauliflower, 
Brussel sprouts and cabbages. Indol-3-carbinol (I3C) is one dietary indole derivative product 
which is transformed by non-enzymatic acid condensation into AhR agonists. The microbiota 
in the gut has the ability to convert such precursors (I3C) into immune regulatory metabolites, 
controlling T cell dependent inflammation; for example in the EAE model275,276. 
In order to test the effect of AhR ligands consumed in the diet in the context of 
autoimmunity and using a spontaneous EAE model, OSE mice were submitted to a chemically 
defined diet (E1500) supplemented or not with I3C2mg/kg. Animals received the corresponding 
diet from birth and the EAE incidence was recorded during the first hundred days of life.  
Control mice received the same diet without the I3C enrichment. The mothers received 
matching diets to their pups from the day they gave birth. The pups remained their whole life 
with the same diet and the mothers were changed back to regular chow after weaning. 
3.1.1 Diet supplementation with an AhR ligand suffices to modify the EAE incidence in 
OSE mice 
Adding one AhR ligand precursor to the chemically defined diet composition, the EAE 
incidence significantly dropped during the first three months of age, when most of the OSE 
mice spontaneously develop the first symptoms. 35.7% (15/42) of the OSE mice fed with the 
chemically defined diet spontaneously developed EAE, whereas only 3.1% (1/32) of the mice 
receiving the I3C enriched diet presented clinical signs (figure 5A).  
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The OSE mice fed from birth with the supplemented diet count with all necessary 
elements to mount an effective immune response and are fully susceptible to EAE induction. 
MOG35-55 immunized OSE mice under the I3C enriched diet were fully capable of developing 
EAE within the two following weeks postimmunization (figure 5B). 
 
Figure 5. Indol-3-carbinol enriched diet abrogates spontaneous EAE development in OSE mice. 
(A) EAE incidence curves using the Kaplan-Meier estimator. OSE mice were fed with the chemically 
defined diet E15000 with or without I3C2mg/kg from birth. Spontaneous EAE development was monitored 
for 100 days. Comparison of EAE incidence curves by log-rank (Mantel-Cox) test. ***p=0.0007. (B) OSE 
mice fed with the I3C enriched diet are fully susceptible to develop EAE if immunized. OSE mice (n=7), 
which remained healthy for 100 days and were fed with I3C were immunized with MOG35-55 and the EAE 
course was monitored for 30 days p.i.  
Since the addition of AhR ligands to the diet seemed to suppress EAE development, 
this work aimed to study which cell types expressing AhR exerted immunoregulatory actions 
and promoted disease suppression in the EAE model. 
3.1.2 AhR deficiency in CD4+ T cells and astrocytes does not influence spontaneous 
EAE in the OSE mouse model 
Among immune cells, the AhR is highly expressed in CD4+ T (helper) cells and dendritic cells 
(DC)123,128. In the CNS, it is strongly expressed in astrocytes126. The aforementioned three cell 
populations contribute to the neuroinflammatory disease process in CNS autoimmune 
diseases at multiple levels92,277. Furthermore, DC and CD4+ T cells are important regulators of 
immune surveillance and host – microbe homeostasis in the intestines via AhR signaling 
pathway137,139. 
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In order to study AhR repercussions in a cell specific manner and taking advantage of 
the Cre-Lox system, AhR was deleted in CD4+ T cells (OSE AhRCD4), DC (OSE AhRDC) or 
astrocytes (OSE AhRAstro) of OSE mice and monitored every other day for EAE symptoms for 
100 days. AhR competent controls (OSE AhRfl/fl) did not differ from their OSE AhRAstro and 
OSE AhRCD4 littermates in EAE onset (figure 6A and D), EAE severity course (6B and E) and 
maximum disease scores (6C and F) respectively.  
Figure 6. AhR deficiency in CD4+ T cells and astrocytes does not influence spontaneous CNS 
autoimmunity in OSE mice. Kaplan-Meier curves are shown to depict spontaneous EAE incidence 
and were compared using log-rank (Mantel-Cox) test. EAE severity was monitored for 30 days from the 
day of EAE onset. Severity curves were analyzed using multiple t tests. Scatter dot plots represent the 
maximum disease severity, shown as mean ± SEM and compared using unpaired t test. No difference 
was found in the EAE incidence, severity and maximum disease severity between OSE AhRGFAP (A, B 
and C) and OSE AhRCD4 (D, F and G) with respect of OSE AhRfl/fl control animals. The number of mice 
is indicated for each graph. 
 
3.1.3 AhR deficiency in DC significantly increases the incidence of spontaneous EAE  
Given the fact that AhR expression in DC plays a central role in their differentiation and function 
and that DC are the most potent activators of naïve T cells; AhR specific ablation in DC was 
fundamental to evaluate AhR function in a T cell mediated model such as EAE. AhR deletion 
in DC doubled the incidence of spontaneous EAE in OSE mice compared to AhR competent 
littermates (figure 7A, ****p<0.0001). 
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Figure 7. AhR deficiency in DC increases the incidence of spontaneous EAE in OSE mice. (A) 
Spontaneous EAE incidence curves were compared by log-rank (Mantel-Cox) test. *** p<0.001. (B) EAE 
disease severity was monitored for 30 days from the day of EAE onset. Severity curves were analyzed 
using multiple t tests. *p<0.05. (C) The number of mildly affected cases increased in OSE AhRDC mice 
shown by a greater scatter in the EAE severity compared to OSE AhRfl/fl littermates. Data represented 
as mean ± SEM and analyzed by unpaired t test. (D) The EAE severity of Th/+ AhRDC is not influenced 
if the mice are actively immunized using MOG1-125. The severity curves were analyzed using multiple t 
tests and showed no significant difference. The number of mice varies and is indicated in each graph. 
Compared to OSE AhRfl/fl control mice, the OSE AhRDC strain was less severely 
affected during the first fourteen days after EAE onset (*p<0.05) and was equally sick at later 
time points (figure 7B). The scattered distribution of the maximum disease severity of OSE 
AhRDC mice revealed that this group contains more diseased mice that are mildly affected. In 
comparison, most OSE AhRfl/fl mice presented high scores and a lower dispersion of the 
maximum EAE severity values (figure 7C).  
Besides using a spontaneous EAE model, DC specific AhR deletion was also evaluated 
in Th/+ mice immunized with MOG1-125 emulgated in CFA. AhR deficiency in DC did not alter 
the EAE incidence or severity in the presence of strong immunostimulants such as CFA (figure 
7D, p>0.05 using multiple t tests). 
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3.2 AhR deficiency in DC alters the phenotype of APCs in the lamina propria of 
OSE mice 
In order to explain the higher incidence of OSE AhRDC compared to OSE AhRfl/fl mice the DC 
and macrophage compartments were analyzed in the LP of OSE mice, where T cell activation 
might take place in the OSE animal model278.  
To discriminate better between DC and macrophages, OSE AhRDC and OSE AhRfl/fl 
were crossed to CX3CR1EGFP reporter mice. Leukocytes from the small intestine were then 
isolated from OSE AhRDC CX3CR1EGFP/+ and OSE AhRfl/fl CX3CR1EGFP/+ animals as described 
in section 2.4.7 and analyzed ex vivo by flow cytometry as explained in 2.4.8. 
 
Figure 8. Gating strategy to assess intestinal APCs. (A) Representative flow cytometry analysis of 
CD45+ intestinal leukocytes divided into the (B, C) DC and (D, E) macrophage compartments. 
Leukocytes were isolated from the small intestines of OSE AhRDC CX3CR1EGFP/+ and OSE AhRfl/fl 
CX3CR1EGFP/+ mice. EGFP expression was measured ex vivo in intestinal LP CD11c+ CD64- DC and 
CD11c- CD64+ F4/80+ macrophages by flow cytometry. 
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OSE AHRΔDC CX3CR1EGFP/+ animals showed a significantly higher percentage of CD45+ 
CD11c+ CD64- DC intermediately expressing CX3CR1 (%CX3CR1int DC = 29.4% ± 2.8) 
compared to OSE AHRfl/fl CX3CR1EGFP/+ mice (18.5% ± 1.6) as shown in figure 9A and B 
(*p=0.03).  
 
 
Figure 9. The percentage of CX3CR1int DC increases in OSE AhRDC CX3CR1EGFP/+ mice compared 
to OSE AhRfl/fl CX3CR1EGFP/+ transgenic animals. (A, B) Quantification of EGFP+ and (A) EGFP- DC 
cell frequencies. (C) MHCII expression (MFI) on EGFP+ or EGFP- DC in OSE AhRDC CX3CR1EGFP/+ and 
OSE AhRfl/fl CX3CR1EGFP/+ transgenic animals. Data are presented as mean ± SEM. Data are pooled 
from at least four independent experiments. *p<0.05, **p<0.01, Mann-Whitney U-test. 
 
MHCII expression was analyzed in CX3CR1int and CX3CR1- CD45+ CD11c+ CD64- DC 
of both OSE AhRDC CX3CR1EGFP/+ and OSE AHRfl/fl CX3CR1EGFP/+ mice by flow cytometry 
analysis. Higher MHCII MFI was observed on CX3CR1+ DC compared to CX3CR1- DC (figure 
9C; **p=0.0025  in OSE AHRfl/fl CX3CR1EGFP/+ mice), suggesting that CX3CR1+ DC might be 
better APCs for CD4+ T cells compared to CX3CR1- DC. 
Furthermore, the presence of LP CX3CR1+ and CX3CR1- DC was detected in paraffin 
embedded sections of the small intestines of CD11ctdTomato CX3CR1eGFP reporter mice (figure 
10). Some DC, which might extend transepithelial dendrites into the lumen of the small 
intestine were detected by immunohistochemistry (figure 11).  
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Figure 10. Visualization of intestinal APCs using the CD11ctdTomato CX3CR1eGFP transgenic mice. 
Mice carrying an eGFP reporter gene under the control of the CX3CR1 promoter and a Cre dependent 
R26tdTomato gene that labels CD11c+ cells upon Cre recombinase activation. Asterisks indicate 
CD11c+CX3CR1+ double positive cells, CD11c+ cells are marked with arrow heads and CX3CR1+ cells 
with arrows. (A, B) overlay, (C, D) tdTomato CD11c+ cells, red. (E, F) eGFP CX3CR1+ cells, green. (G, 
H) CD11ctdTomato and (I, J) CX3CR1eGFP single transgenic mice are shown as controls. A, C, E, G and I 
were acquired using 400x magnification. B, D, F and H are the corresponding insets at 1000x 
magnification. 
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Figure 11. DC might sample luminal antigens by small transepithelial dendrites. Intestinal sections 
of CD11ctdTomato CX3CR1eGFP reporter mice. (A, D) overlay, (B, E) tdTomato CD11c+ cells, red. (C, F) 
eGFP CX3CR1+ cells, green. A, B and C were acquired using 400x magnification. D, E and F are the 
corresponding insets at 1000x magnification. 
As shown in figure 8D and E and quantified in figure 12A fewer cells in the lamina 
propria of OSE AhRDC CX3CR1EGFP/+ mice compared to OSE AHRfl/fl control littermates were 
bona fide macrophages defined as CD45+ CD64+ F4/80+ CX3CR1high. Interestingly, also the 
macrophage population in OSE AhRDC CX3CR1EGFP/+ compared to the macrophage 
population in OSE AHRfl/fl mice harbored a more activated phenotype as suggested by 
downregulation of F4/80 (figure 8D and E) and upregulation of MHCII (figure 12B, MFI=20333 
± 865 in OSE AHRΔDC CX3CR1EGFP/+ mice compared to MFI=17467 ± 706 in control mice). 
 
Figure 12. OSE AhRDC CX3CR1EGFP/+ mice showed reduced numbers of intestinal LP 
macrophages compared to OSE AhRfl/fl CX3CR1EGFP/+ control animals. (A) Percentage of CD64+ 
F4/80+ CX3CR1high macrophages among CD45+ leukocytes in the LP of OSE AhRDC CX3CR1EGFP/+ 
compared to OSE AhRfl/fl CX3CR1EGFP/+ mice (B) MHCII MFI of CD64+ F4/80+ CX3CR1high LP 
macrophages. Data are shown as mean ± SEM. * p<0.1, Mann-Whitney U-test. 
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To improve the tools to dissect the difference between AhR competent and AhR 
deficient DC, AhRfl/+ CD11cCre+ R26ReYFP and AhRfl/- CD11cCre+ R26ReYFP mice were generated. 
The former mice have YFP tagged AhR competent DC and the latter YFP tagged AhR deficient 
DC.  
High frequencies of YFP+ cells were observed among the DC purified from the spleens 
of both transgenic strains using MACS separation (figure 13B and C). An upregulation of the 
AhR reporter gene, CYP1A1, was observed in YFP+ AhR competent DC in response to the 
potent AhR agonist, FICZ, while no changes were observed in YFP+ AhR deficient DC.  
Thus, these preliminary experiments suggest that the AhRfl/+ CD11cCre+ R26ReYFP and 
AhRfl/- CD11cCre+ R26ReYFP mice might be valuable tools to purify AhR competent and AhR 
deficient DC ex vivo for functional studies.  
 
Figure 13. Quantification of CYP1A1 expression in YFP+ AhR competent and AhR deficient DC. 
(A) Representative FACS dot plot of the forward and side scatter of the splenic cells obtained from the 
transgenic lines. (B) YFP expression of DC purified from AhRfl/+ CD11cCre+ R26ReYFP and (C) AhRfl/- 
CD11cCre+ R26ReYFP mice was analyzed by flow cytometry. (D) Expression of CYP1A1 was quantified 
by qPCR after FICZ stimulation. 
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3.2.1 OSE AhRDC mice present increased numbers of IFNγ+ transgenic T cells in the 
lamina propria of the small intestine 
In order to test if the higher percentage of CX3CR1int DC in OSE AhRDC CX3CR1EGFP/+ 
compared to OSE AhRfl/fl CX3CR1EGFP/+ mice translates into higher frequencies of cytokine 
producing CD4+ T cells, intestinal leukocytes were isolated from the lamina propria and 
stimulated with PMA and ionomycin (figure 14B and D). Unstimulated cells were used as 
controls (14A and C).  
 
Figure 14. OSE AhRDC mice have significantly higher frequencies of IFN producing MOG 
specific T cells in the lamina propria of the small intestines. (A, B) Representative flow cytometry 
analysis of intestinal Vα3.2 CD4+ T cells obtained from the small intestines of OSE AhRfl/fl control mice 
and (C, D) OSE AhRDC littermates. (E) The production of IL17 and (F) IFNγ was quantified ex vivo by 
flow cytometry after stimulation with PMA and ionomycin. Data are presented as percentage of the total 
number of transgenic CD4+ T cells and shown as mean ± SEM. * p=0.038, Mann-Whitney U-test. 
 
Cytokine secretion was blocked with Golgi Stop and intracellular detection of IL17 and 
IFNγ was performed by flow cytometry in Vα3.2+ MOG specific TCR transgenic CD4+ T cells 
(described in section 2.4.8.3). A significantly higher frequency of IFNγ (figure 14B, D and F) 
but not IL17 (figure 14B, D and E) producing transgenic CD4+ T cells were detected in response 
to stimulation with PMA and Ionomycin in OSE AhRDC animals compared to OSE AHRfl/fl 
control littermates.   
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3.2.2 OSE AhRDC mice have significantly higher MOG specific IgG2a antibody titers 
IFNγ is known to promote isotype switching to IgG2a production279. Thus, anti-MOG IgG1 and 
IgG2a antibody titers were quantified in the sera of OSE AhRDC and OSE AHRfl/fl mice by 
ELISA performing 5-fold serial dilutions starting at 1:500 as described in section 2.4.13. 
Significantly higher MOG specific IgG2a (figure 15B) but not IgG1 antibody titers (15A) were 
found in OSE AhRDC compared to OSE AHRfl/fl mice at 1:500 (**p=0.008) and 1:2500 dilutions 
(*p=0.012). 
 
Figure 15. Quantification of MOG specific antibody titers in the sera of OSE AhRDC and OSE 
AHRfl/fl mice by ELISA. (A) IgG1 and (B) IgG2A anti-MOG antibody concentrations were measured in 
the serum of sick OSE AHRDC and OSE AhRfl/fl mice by indirect ELISA. Serum obtained from healthy 
WT animals was used as a negative control. Nonspecific binding to BSA was subtracted from all values 
to calculate the mean absorbance (OD 450 nm) and compared by multiple t tests. * p<0.05, ** p<0.01. 
 
3.3 AhR competent DC are relevant for Laquinimod to suppress EAE 
Laquinimod, a quinoline-3-carboxamide derivative, is an oral DMT with moderate efficacy 
against RRMS280. Previous EAE experiments have suggested that the immunomodulatory 
properties of Laquinimod might be attributed to its ability of promoting the shift of 
proinflammatory immune cells towards less immunogenic and more regulatory phenotypes.  
Daily oral treatment with Laquinimod from the day of immunization ameliorates or 
completely abolishes acute EAE development in C57BL/6 mice183. In particular, Laquinimod 
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treatment decreases the immunogenicity of DC, reduces the frequency of proinflammatory 
IFNγ and IL17 producing T cells and increases the percentage of Tregs182. In addition, the 
modulation of nonimmune cells such as astrocytes189 and endothelial cells192 might be relevant 
for Laquinimod’s therapeutic efficacy in EAE.  
Recent results demonstrated that Laquinimod’s ability to suppress EAE is greatly 
decreased in AhR KO mice193,194. Therefore, the therapeutic efficacy of Laquinimod was 
evaluated in cell specific AhR deficient mice immunized with MOG35-55. 
3.3.1 Laquinimod’s therapeutic effect cannot be attributed to a single AhR competent 
cell type  
EAE was actively induced by MOG35-55 immunization (as described in section 2.4.2) in AhRΔCD4, 
AhRΔTreg, AhRΔAstro AhRΔDC and AhRfl/fl control mice treated with Laquinimod (25 mg/kgbody weight) 
or vehicle from the day of immunization (section 2.4.4). EAE incidence, onset and maximum 
disease score were recorded for all transgenic lines in table 22. Animals were handled and 
scored as explained in 2.4.3 (scoring scale described in table 20). 
 Vehicle Laquinimod 
 Incidence 
Max. 
Score 
Disease 
Onset 
Incidence 
Max. 
Score 
Disease 
Onset 
AhRfl/fl 28/41 2.92 ± 0.84 16.03 ± 4.17 3/44 2.83 ± 0.58 23.00 ± 1.73 
AhRΔDC 9/10 3.06 ± 0.73 17.00 ± 4.18 7/11 2.42 ± 0.53 23.00 ± 2.28 
AhRΔAstro 20/20 3.37 ± 0.55 15.45 ± 3.16 5/20 3.25 ± 0.50 17,4 ± 1.81 
AhRΔTreg 12/18 3.37 ± 0.70 14.33 ± 3.17 1/16 3 22 
AhRΔCD4 7/12 2 ± 1 17.28 ± 5.61 2/11 2.75 ± 0.35 19 ± 7.07 
 
Table 22. EAE incidence, maximum disease score and EAE onset. Cell specific AhR deficient mice 
were immunized with MOG35-55 and treated with Laquinimod or vehicle. Incidence, maximum disease 
score of clinically affected mice and EAE onset were assessed for 30 days post immunization and 
presented as mean ± SD. AhRfl/fl littermates were used as controls. 
 
 
Vehicle treated AhRfl/fl control mice developed EAE in 68% of the cases (28/41). The 
EAE incidence in vehicle treated AhRΔCD4, AhRΔTreg, AhRΔDC, AhRΔAstro varied between 58% 
(AhRΔCD4), 67% (AhRΔTreg), 90% (AhRΔDC) or 100% (AhRΔAstro) respectively and was 
significantly different between vehicle treated AhRΔAstro and AhRfl/fl controls (figure 18B). 
  
61 Results 
 
 
Figure 16. The Laquinimod mediated EAE incidence decrease is less sustained in AhRΔDC mice. 
(A) EAE incidence curve of AhRfl/fl control group, (B) AhRΔDC, (C) AhRΔTreg, (D) AhRΔAstro and (E) AhRΔCD4 
animals. AhR was deleted in specific cell populations including DC (CD11cCre), Tregs (FoxP3Cre), 
astrocytes (GFAPCre) and CD4+ T cells (CD4Cre) using the Cre lox system. Mice were daily monitored 
and treated with Laquinimod (25 mg/kgbody weight) or vehicle from the day of immunization to day 30 p.i. 
Data are shown as mean ± SEM and are representative of three to five independent experiments. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, Log-rank (Mantel-Cox) test. 
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The disease onset was comparable between all vehicle treated cell specific AhR 
deficient mice and vehicle treated AhRfl/fl controls. The maximum disease scores of the affected 
animals were slightly higher in mice with AhR deficiency in astrocytes and Tregs. 
Laquinimod administration delayed the development of EAE symptoms and decreased 
the EAE incidence in AhRfl/fl control animals and in all cell specific AhR deficient mice compared 
to littermates treated with water. However, this protective effect was less sustained in AhRΔAstro 
(figure 16D) and particularly in AhRΔDC mice (figure 16B). In descending order, 64% of AhRΔDC, 
25% of AhRΔAstro, 18% of AhRΔCD4 and 6% of AhRΔTreg mice developed disease if treated with 
laquinimod compared to 6.8% of mice in AhRfl/fl controls. 
3.3.2 AhR competent DC contribute to Laquinimod’s protection against EAE 
Laquinimod significantly protected AhRΔDC mice against EAE induced by active immunization 
evidenced by a delayed disease onset (EAE onset of vehicle treated AhRΔDC mice at day 17 ± 
4.18 and EAE onset of Laquinimod treated AhRΔDC mice at day 23 ± 2.28) and a reduction of 
the mean maximum score of the clinically affected animals compared to vehicle treated AhRΔDC 
mice (vehicle treated = 3.06 ± 0.73 and Laquinimod treated = 2.42 ± 0.53).  
Nonetheless, the protective effect of Laquinimod was not as sustained as in 
Laquinimod treated AhRfl/fl mice (figure 16A and 17A) and a significant number of AhRΔDC 
animals developed mild EAE symptoms during the last 10 days of the observation period 
(figure 16B, 17B and 18G).  
Laquinimod was also therapeutically effective in AhRΔAstro mice (figure 16D and 17D). 
Of note, vehicle treated AhRΔAstro mice harbored more severe EAE than vehicle treated AhRfl/fl 
mice (figure 18B and F). Therefore, the slight increase of unprotected Laquinimod treated 
AhRΔAstro mice compared to Laquinimod treated AhRfl/fl mice might reflect an increased 
susceptibility of AhRΔAstro mice to develop EAE rather than a necessity of the astrocytic AhR 
mediating the protective effect of Laquinimod (figure 18D and H).  
Laquinimod treatment protected AhRΔCD4 (figure 16E and 17E) and AhRΔTreg mice 
(figure 16C and 17C) compared to AhRfl/fl littermates. As shown in table 22, the disease onset 
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was delayed from day 14.33 ± 3.17 (control group) to 22 in the AhRΔTreg Laquinimod treated 
group and there was a slight reduction of the mean maximum score of the diseased mice 
(AhRΔTreg vehicle treated = 3.37 ± 0.70 and Laquinimod treated = 3). 
 
Figure 17. Expression of AhR on DC, Tregs and astrocytes is not essential for Laquinimod 
mediated decrease of EAE severity. Cell specific AhR KO mice were MOG35-55 immunized and daily 
treated with Laquinimod (25 mg/kgbody weight). Oral administration of the drug or vehicle started on the day 
of immunization to day 30 p.i. (A) Disease severity curves of AhRfl/fl control mice, (B) AhRΔDC, (C) 
AhRΔTreg and (D) AhRΔAstro mice. Data are shown as mean ± SEM and represent three independent 
experiments. AhRfl/fl mice were used as control group (A). *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. All severity curves were analyzed using multiple t tests. 
  
64 Results 
 
Figure 18. Laquinimod´s effect on AhRΔAstro and AhRΔDC. (A) EAE incidence curves corresponding 
to vehicle treated AhRΔDC, (B) vehicle treated AhRΔAstro. AhR deficiency in GFAP+ but not in CD11c+ cells 
potentiates EAE incidence and does not affect Laquinimod’s protective effect. (C) Graphs representing 
the EAE incidence of Laquinimod treated AhRΔDC and (D) Laquinimod treated AhRΔAstro. AhR expression 
in CD11c+ cells is not essential but plays a role in the Laquinimod mediated EAE inhibition, while AhR 
deficiency in GFAP+ cells is not required. (E) EAE severity curves obtained from Laquinimod treated 
AhRΔDC and (F) vehicle treated AhRΔAstro. Data are shown as mean ± SEM and represent three to four 
independent experiments. AhR competent (AhRfl/fl) mice were used as control group and are 
represented with dotted lines. The EAE incidence curves of AhRΔAstro and AhRΔDC mice are depicted 
with solid lines. ** p<0.01, ****p<0.0001, Log-rank (Mantel-Cox) test. The EAE severity curves of 
AhRΔAstro and AhRΔDC mice were analyzed by multiple t tests. * p<0.1, ** p<0.01 and ****p<0.0001. 
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Laquinimod was able to significantly reduce EAE in all cell specific AhR KO lines 
compared to vehicle treated littermates. Even though Laquinimod significantly protected 
AhRΔDC mice against EAE compared to AhRfl/fl littermates (p=0.001), fewer number of animals 
were fully protected, arguing for a moderate effect of AhR competent DC mediating the 
therapeutic efficacy of Laquinimod.  
3.3.3 Laquinimod treatment reduces the percentage of CD11c+MHCIIhigh DC cells in 
AhRΔDC mice 
To date, different mechanisms have been proposed to describe how Laquinimod could 
suppress EAE. Previous results obtained in C57BL/6 mice suggested that APCs such as 
CD11c+CD11b+CD4+ DC were reduced and CD11b+ cells were modulated towards an anti-
inflammatory phenotype180,182.  
Ex vivo and in vivo experiments displayed a reduction of MHCII, costimulatory 
molecules (CD80, CD86) and the activation marker CD40 on DC and macrophages after 
Laquinimod therapy281, suggesting that T cell activation and proliferation might be indirectly 
impaired282. Hence, it was tested if a reduction of CD11c+ MHCIIhigh DC can be still observed 
in Laquinimod treated AhRΔDC mice, but also in AhRΔCD4, AhRΔAstro and AhRΔTreg mice.  
All Cre lines and AhRfl/fl controls were treated with vehicle or Laquinimod from the day 
of immunization. At day 10 splenic CD11c+ MHCIIhigh DC were evaluated ex vivo by flow 
cytometry as explained in 2.4.8. 
All Laquinimod treated mice, including AhRΔDC animals, had reduced DC frequencies 
compared to control litermates. AhRΔDC p=0.036, AhRΔTreg p=0.009, AhRΔAstro: p=0.001, 
AhRΔCD4 p=0.003, corresponding to figure 19B, C, D and E. AhRfl/fl animals were used as 
controls (figure 19A, p=0.002). 
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Figure 19. Laquinimod decreases the percentage of CD11c+MHCIIhigh DC in AhRΔDC mice. 
Representative dot plots of CD11c and MHCII expression in CD45+ CD19- cells of MOG35-55-immunized 
(A) AhRfl/fl, (B) AhRΔDC, (C) AhRΔTreg, (D) AhRΔAstro and (E) AhRΔCD4 mice, which were treated daily with 
Laquinimod (25 mg/kgbody weight) or vehicle from the day of immunization to day 10 p.i. Bar graphs depict 
the percentage of CD11c+ MHCIIhigh cells among total CD45+ cells. Data are shown as mean ± SEM.. 
*p<0.05, **p<0.01.  Mann-Whitney U-test. 
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3.3.4 Laquinimod requires AhR competent DC to reduce the frequency of Th17 cells  
Previous studies performed in Laquinimod treated mice showed that the frequency of 
proinflammatory Th1 or Th17 CD4+ T cells decreases whereas the numbers of Tregs increase 
in the periphery182 and CNS196.  
In addition, it was demonstrated that AhR is involved in the development of Th17 cells, 
as well as in the production of IL17 and IL22 cytokines283. Until now, it remains unclear if 
Laquinimod directly interacts with T cells or if the shift towards anti-inflammatory T cell 
populations is indirectly induced by the drug. 
Splenocytes were ex vivo stimulated with PMA and ionomycin to induce cytokine 
production. Monensin and brefeldin were added to the cultures in order to block protein 
transport and to promote cytokine accumulation in the Golgi complex. Intracellular staining of 
IL17 and IFNγ was analyzed by flow cytometry in splenic CD45+CD19 -CD3+ CD4+ T cells as 
explained in section 2.4.8.3. 
Preventive treatment with Laquinimod significantly decreased 3 to 4-fold the number of 
IL17 producing CD4+ T cells in AhRfl/fl control mice (p=0.004), as well as in AhRAstro, (0.002) 
and AhRCD4 (p=0.004) corresponding to figure 20A, C and D.  
Interestingly, Laquinimod failed to significantly decrease the percentage of IL17 
producing CD4+ T cells in AhRΔDC mice (figure 20B; p=0.1), suggesting that the reduction of 
proinflammatory cytokine producing CD4+ T cells is indirectly mediated via AhR competent DC. 
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Figure 20. Laquinimod fails to decrease IL17 producing CD4+ T cells in AhRDC mice but not in 
AhRCD4 and AhRΔAstro. Representative flow cytometry analysis of the IL17 producing CD4+ T cells 
isolated from (A) AhRfl/fl control mice, (B) AhRΔDC, (C) AhRΔAstro and (D) AhRΔCD4 animals treated daily 
with Laquinimod (25 mg/kgbody weight) or vehicle from the day of immunization to day 10 p.i. IL17 producing 
T cells were ex vivo analyzed by flow cytometry following stimulation with PMA and ionomycin. Data are 
presented as percentage from the total number of CD4+ T cells shown as mean ± SEM and are 
representative from three different experiments. * p<0.1, **p<0.01, Mann-Whitney U-test. 
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3.3.5 The AhR-IDO-1 axis does not mediate Laquinimod’s protective effect in the EAE 
model 
AhR signaling is required for the expression of indoleamine 2,3 dioxygenase (IDO) in DC, an 
immunosuppressive enzyme that catabolizes tryptophan into kynurenine168,174,284. 
Furthermore, the absence of the AhR in bone marrow derived DC skewed the differentiation 
of naïve T cells towards Th17 and inhibited the differentiation into Tregs285. 
To assess whether the AhR-IDO-1 signaling loop contributes to the efficacy of 
Laquinimod to suppress EAE, IDO-1 KO mice and C57BL/6 controls were immunized with 
MOG35-55 and treated with vehicle or Laquinimod for 30 days from the day of immunization. 
Laquinimod inhibited EAE regardless of IDO-1 deletion. IDO-1 competent (p=0.0003), as well 
as IDO-1 KO mice (p=0.0007) were fully protected by Laquinimod administration from day 16 
onwards compared to vehicle treated animals (figure 21). 
 
 
Figure 21. The lack of IDO-1 does not impair Laquinimod’s protection against EAE. IDO-1 KO and 
C57BI/7 mice were immunized with MOG35-55 and treated daily with vehicle or Laquinimod (25 mg/kgbody 
weight) from the day of immunization to day 30 p.i. Data are shown as mean ± SEM. ****p<0.0001, 
Laquinimod versus vehicle treated groups were analyzed by multiple t tests. Control littermates were 
treated with water as vehicle. n=10 for each of the four experimental groups. 
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3.3.6 Laquinimod increases CD25+ FoxP3+ T cells in AhRΔCD4 and AhRΔTreg mice 
Laquinimod was previously shown to promote anti-inflammatory conditions by significantly 
decreasing Th1 and Th17 responses190 and favoring Tregs differentiation and expansion in the 
CNS196 and periphery182.  
Different groups have shown that acutely immunized mice with MOG35-55 and daily 
treated from the day of immunization with the AhR agonist, Laquinimod, present an elevation 
of the percentage of splenic CD4+ CD25+ Foxp3+ cells compared to vehicle treated 
animals194,196,286. 
 On the other hand, it is known that AhR signaling triggered by physiological ligands is 
an important regulator of murine and human Tregs diferentiation137. Furthermore, Laquinimod 
treatment has been shown to be unable to alter Tregs frequencies in AhR KO mice compared 
to control littermates194.  
As a subpopulation of CD4+ T cells, Tregs were defined by the expression of the 
transcription factor FoxP3 and the surface marker CD25 as shown in figure 22. Flow cytometry 
analysis (described in section 2.4.8.2) showed that Laquinimod treatment increased the 
percentage of Tregs in EAE mice devoid of AhR in DC (p=0.0007), Tregs (p=0.0002) and CD4 T 
cells (p=0.03), corresponding to figure 22B, C and D, as well as in AhRfl/fl control animals (figure 
22A, p=0.005).  
In contrast to an impaired suppression of Th17 cells in AhRDC mice treated with 
Laquinimod, AhR competent DC, CD4+ T cells or FoxP3+ T cells were not required in 
Laquinimod treated mice to increase the percentage of Tregs. 
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Figure 22. Laquinimod increases the percentage of CD25+FoxP3+ cells in AhRΔDC, AhRΔTreg and 
AhRΔCD4 animals. Representative FACS dot plots showing the expression of CD25 and FoxP3 in T cells 
of (A) AhRfl/fl control mice, (B) AhRΔDC, (C) AhRΔTreg and (D) AhRΔCD4 animals treated with Laquinimod 
(25 mg/kgbody weight) or vehicle from the day of immunization to day 10 p.i. CD25+ FoxP3+ cells were ex 
vivo analyzed by flow cytometry and presented as percentage from the total lymphocyte count (CD45+ 
cells), except for the cells obtained from AhRΔTreg mice (YFP labeled FoxP3+ cells), which are expressed 
as a percentage of the CD19-CD3+ cells. Data are shown as mean ± SEM and are pooled from three 
independent experiments. *p<0.05, **p<0.01, ***p<0.001, Mann-Whitney U-test. 
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3.3.7 NK cell activation by Laquinimod is independent of AhR expression on DC and 
CD4+ T cells 
NK cells are effectors of the innate immune system that constantly monitor stressed, infected 
or abnormally proliferating cells. NK cells belong to the innate lymphoid cell (ILC) family287, 
which has been shown to require AhR signaling in many of its subsets to differentiate and 
survive288. It has been shown that AhR activation through tryptophan derived ligands 
potentiates NK cell activation leading to cytokine production, cytolytic and tumor control 
activity289. 
The interplay between NK and DC potentially elicits cell activation and maturation of 
both cell types and impacts on CD4+ T cell responses290. Previous work from our group has 
shown that Laquinimod activates NK cells in vivo and in vitro and CD69 was among the NK 
cell markers upregulated by laquinimod treatment. 
Ex vivo purified NK cells from Laquinimod treated mice killed B16F10 melanoma cells 
in vitro more efficiently than NK cells isolated from vehicle treated littermates. Furthermore, in 
a co-culture system with DC and MOG specific CD4+ T cells, NK cells from Laquinimod treated 
mice inhibited T cell proliferation better than NK cells from vehicle treated animals. This 
inhibition required cell to cell contact of NK cells with DC. Additionally, the depletion of NK cells 
impaired the efficacy of Laquinimod to suppress EAE [in revision]. 
In order to evaluate NK cell activation in response to Laquinimod administration and in 
the absence of AhR in different immune cell players relevant for its signaling, expression of the 
activation marker CD69 was measured by flow cytometry in splenic NK cells obtained from 
AhRΔDC, AhRΔTreg, and AhRΔCD4 mice immunized with MOG35-55.  
Laquinimod treatment increased the early activation marker CD69 in NK cells obtained 
from AhRfl/fl control mice (figure 23A, p=0.032) and all cell specific AhR KO mice, including 
AhRΔDC (p=0.029), AhRΔTreg (p=0.015) and AhRΔCD4 mice (p=0.006) corresponding to figure 
23B, C and D, as well as in their corresponding AhR competent controls (p=0.022, 0.0003, 
0.022).  
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Figure 23. Laquinimod activates NK cells in the absence of AhR competent CD4+ T cells or DC. 
FACS histograms of CD69 expression on the surface of splenic NK cells obtained from (A) AhRfl/fl control 
mice, (B) AhRΔDC, (C) AhRΔTreg and (D) AhRΔCD4 animals treated with Laquinimod (25 mg/kgbody weight) or 
vehicle from the day of immunization to day 10 p.i. The CD69 MFI of the bar graphs is depicted as mean 
± SEM pooled from 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001, Mann-Whitney U-test. 
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3.3.8 Laquinimod reduces pulmonary B16F10 metastases 
 
NK cells’ antitumor functions have been extensively studied in different cancer models291. They 
are usually more effective impairing the metastatic spread of malignant cells in the blood 
stream than reducing the size of established tumors. In vivo and in vitro approaches have 
previously shown that AhR activation enhances the anti-tumor properties and cytolytic activity 
of NK cells in the murine model289,292. 
Laqunimod mediated control of B16F10 melanoma metastases was evaluated in vivo 
using two experimental approaches. In a first model Laquinimod was preventively 
administrated to C57BL/6 and AhR KO mice before i.v. injection of B16F10 melanoma cells  
(figure 24A). In a second model the treatment of Laquinimod was initiated in C57BL/6 mice 
with established metastases 11 days after i.v. B16F10 melanoma cell injection (figure 24B). 
 
Figure 24. Preventive and therapeutic approaches used to study the efficacy of Laquinimod to 
suppress B16F10 melanoma metastases in vivo. Timelines corresponding to the (A) preventive and 
(B) therapeutic approaches. Animals submitted to the preventive treatment received daily Laquinimod 
administration starting three days before the i.v. transfer with 0.5x106 B16F10 melanoma cells and the 
lungs were isolated 10 days after inoculation. Mice under a therapeutic regimen were sacrificed 19 days 
after i.v. injection of 0.2x106 B16F10 melanoma cells and Laquinimod treatment was started 11 days 
after tumor inoculation. 
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 Laquinimod was administrated in a dosis of 50 mg/kgbody weight and vehicle treated 
littermates were used as control. After preventive or therapeutic regimens the mice were 
sacrificed and the metastasic burden was quantified in the lungs as described in 2.4.12.3. 
C57BL/6 animals preventively treated with Laquinimod showed a decrease in the 
number of metastasic colonies in the lungs (figure 25B) compared to vehicle treated mice 
(p=0.04). These results were confirmed by assesing the total lung weight, showing that the 
lungs obtained from mice receiving Laquinimod weighted significantly less (p=0.001) than 
those isolated from control animals (figure 25A).  
When the same experiment was repeated with Laquinimod or vehicle treated AhR KO 
animals, the drug’s protective effect was abolished. Vehicle treated AhR KO animals had less 
pulmonary metastases than vehicle treated C57BL/6 mice, which were not further reduced by 
laquinimod treatment. (figure 25D). In addition, Laquinimod was ineffective to reduce the 
number of already established pulmonary metastases (figure 25C). 
 
Figure 25. Laquinimod reduces the number of pulmonary B16F10 metastases if given 
preventively. (A)  Pre-fixation total lung weight and (B) number of pulmonary metastatic colonies 
observed in WT mice receiving preventive daily oral gavage of Laquinimod 50mg/kgbody compared to 
water treated controls. (C) Number of pulmonary B16F10 metastases of mice submitted to the 
therapeutic regimen. (D) Number of pulmonary metastases in B16F10 melanoma cell-transferred 
C57BL/6J and AhR-/- mice treated with Laquinimod or vehicle prior to the tumor cell challenge. 
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4 .  D I SCUSSIO N 
There is increasing evidence that the gut microbiome found in demyelinating CNS diseases 
such as MS and NMO might differ from the gut microbiome found in healthy controls293–296. 
While the causality of these findings needs to be clarified in the light of potential confounders 
from comorbidity to concomitant medications, growing experimental evidence from a number 
of transgenic animal models shows that the germ status of the animal facility influences the 
incidence of spontaneous autoimmunity as in MBP TCR transgenic mice297. Dysbiosis of the 
gastrointestinal microflora promotes the differentiation of proinflammatory T cells and organ-
specific autoimmunity118,121. OSE mice raised in germ-free conditions are impervious to 
spontaneous EAE103, suggesting that the intestinal microbiome contributes to the priming of 
pathogenic transgenic T cells. 
The AhR is a ligand activated transcription factor that participates in broad molecular 
interactions, including the interplay of the immune system, diet and microbiome. The last two 
provide a wide range of AhR ligands leading to different effects on immune homeostasis such 
as control of Tregs and Th17 responses, dampen of DC maturation and regulation of 
gastrointestinal tolerance or inflammation mechanisms74. The present study is mainly focused 
on the influence of AhR expression in CNS autoimmunity and its modulation by natural ligands 
that can be ingested through the diet.  
In the first part, a dramatic decrease in the spontaneous EAE incidence was observed 
in the OSE mouse model after altering one AhR ligand in their diet. Next, the repercussions of 
the specific AhR deletion in astrocytes and immune cells, such as DC, CD4+ T cells and Tregs, 
were evaluated in the spontaneous EAE incidence, maximum disease scores and EAE 
severity of the OSE mice. Due to the effect of AhR deletion in DC, which significantly increased 
the disease incidence in this transgenic line, a closer look was taken into the APCs 
compartment and the CD4+ T cell proinflammatory cytokines production of the OSE mice. 
 
  
77 Discussion 
 
Figure 26. Graphical summary of the observed effects in the OSE mouse model harboring an 
AhR deletion in DC. Schematic representation of the small intestines of OSE AhRfl/fl CX3CR1EGFP/+. 
OSE mice lacking AhR in DC showed higher frequencies of LP CX3CR1int DC (depicted in green) and 
IFNy producing Vα3.2+ MOG specific TCR CD4+ T cells (depicted in red-brown). Isotype switching 
towards IgG2a secretion was enhanced and the spontaneous EAE incidence in OSE AhRDC 
CX3CR1EGFP/+ mice doubled in comparison to their OSE AhR competent littermates. DC might capture 
luminal antigens by extending transepithelial dendrites. 
 
As shown in the graphical summary (figure 26), the specific AhR deletion in CD11c+ 
cells led to an increase in the frequencies of CX3CR1int DC compared to CX3CR1- DC 
measured in the LP of the OSE AhRDC CX3CR1EGFP/+ reporter mice. Besides, higher 
expression of MHCII was quantified in CX3CR1int DC, suggesting that OSE AhRDC 
CX3CR1EGFP/+ might exhibit DC that are better prepared for antigen presentation. In addition, 
a discrete increase of the IFNy producing Vα3.2+ MOG specific TCR CD4+ T cells was shown 
in the LP of these transgenic animals, which supports the increase of IgG2a secretion 
measured in the OSE mice sera.  
In the last part, Laquinimod, a presumed AhR ligand known by its immunomodulatory 
effects in DC and CD4+ T cells, was tested in AhR specific KO animals. Laquinimod’s 
therapeutic effect seemed to be attenuated by AhR expression in DC. On the one hand, all 
transgenic mice with AhR deletion in DC, CD4+ T cells, Tregs or astrocytes, were protected from 
  
78 Discussion 
EAE by the drug, even though in a less sustained way in AhRDC mice. On the other hand, the 
frequencies of IL17 producing CD4+ T cells were reduced in mice lacking AhR in CD4+ T cells 
but not in animals devoid of AhR in DC. 
4.1 AhR deletion in DC doubles disease incidence in the OSE mouse model 
Research conducted in AhR KO mice has shown important implications on Th17 and Tregs 
responding to AhR signals. Yet there was no previous evidence on a spontaneous EAE model 
reporting the particular repercussions of AhR specific deletion in DC, astrocytes and CD4+ 
cells. 
The data presented in figure 7A showed that the lack of AhR in DC doubles the 
occurrence of spontaneous CNS autoimmunity in the OSE mice. This results support that 
physiological AhR ligands in the regular animal diet influence the development of spontaneous 
CNS autoimmunity via AhR competent DC288.  
AhR ablation in CD11c+ (figure 7A) cells but not in GFAP+ and CD4+ (figure 6A and D) 
led to a significant increase in the spontaneous EAE incidence suggesting important regulatory 
functions of AhR signaling in DC and certain macrophages subsets.  
DC are the most potent APCs modulating immune responses and they express high 
AhR protein levels131. Intestinal DC have important functions maintaining the integrity of the 
epithelial barrier by continuously sensing gut lumen antigens. Due to their close proximity to 
commensal bacteria, the activation status of intestinal DC and APCs has to be tightly regulated. 
Imbalanced APCs might contribute to the development of gut specific autoimmunity298,299. 
AhR in DC has been demonstrated to act through the Wnt signaling regulating mucosal 
immunity and development. For example, AhR deficient DC have a direct effect in the intestine 
morphogenesis affecting the differentiation of secretory epithelial cells, such as goblet and 
Paneth cells173. Impairment of AhR in DC is enough to elicit gut epithelium dysfunction and to 
increase the propensity to bowel inflammation. The disruption of the intestinal epithelium’s 
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integrity is considered an early EAE event, which may support disease progression and 
worsening300.  
AhRfl/+ CD11cCre+ R26ReYFP and AhRfl/- CD11cCre+ R26ReYFP mice were generated in 
order to sort out AhR competent and AhR deficient DC ex vivo. More than 90% of the MACS 
purified DC were YFP labeled. Besides, CYP1A1, a prototypic AhR regulated gene, is readily 
induced by FICZ in sorted YFP+ DC of AhRfl/+ CD11cCre+ R26ReYFP mice (AhR competent), but 
not in YFP+ DC purified from AhRfl/- CD11cCre+ R26ReYFP mice (AhR deficient). Thus, this model 
might be valuable to further dissect the DC phenotype and to generate functional data with 
AhR competent or deficient DC. 
4.2 Evaluation of intestinal APCs in the OSE AHRΔDC mice 
Taking a closer look into the intestinal APCs compartment, AhR deficient and AhR competent 
DC were characterized in OSE AHRΔDC and OSE AHRfl/fl mice, respectively. Since the LP is 
the mucosal effector site where most of the APCs reside and contribute to the gastrointestinal 
immune system, DC were obtained and characterize from this compartment. 
DC have a unique feature that allows them to migrate from the intestine to the 
mesenteric lymph nodes in the vicinity starting adaptive immune responses by priming naive 
T cells. Macrophages are LP residents and thus, unlikely to play a major role in the priming of 
naive cells. As innate effector cells, macrophages engulf and clear bacteria, secrete cytokines, 
and maintain intestinal homeostasis They are also very abundant and express CD11c+ in some 
subsets, which is considered a prototypical DC marker301–304. 
Besides the ability to migrate, the intestinal APCs can be differentiated by the 
expression of cell surface markers. The chemokine receptor CX3CR1 (fractalkine receptor) 
and the high affinity IgG receptor FcγR CD64 were used to evaluate the different APCs 
population through a consistent gating approach. The fractalkine receptor (CX3CR1) is often 
used to characterize functionally and phenotypically different subsets of the intestinal immune 
cells, being present in the LP DC (CX3CR1int)  and macrophages (CX3CR1high)301,302,305,306.  
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The lack of AhR in DC affected the composition of the APCs compartment in the lamina 
propria of the OSE AhRDC CX3CR1EGFP/+ reporter mice by increasing the percentage of 
CX3CR1int DC while decreasing the percentage of CX3CR1- DC.  
Initial studies using CX3CR1EGFP/+ reporter mice suggested that DC could extend 
transepithelial dendrites (TED) through tight junctions in the epithelium to capture luminal 
bacteria307. Further studies proposed that TED formation was CX3CR1 dependent308 
In addition, CD64 expression was used to distinguish DC from macrophages within the 
lymphocytes isolated from the gut (figure 8). Until now, CD64 seems to be the most reliable 
intestinal macrophage marker in the small and large bowel of humans and mice, under 
inflammation or steady state306,309 to unambiguously discriminate CX3CR1int (CD64-) DC from 
CD11c+ (CD64+) macrophages.  
Furthermore, the murine receptor F4/80 expressed in most tissue resident 
macrophages310 was used to further characterize intestinal APCs, even though it is present in 
some DC subtypes, such as CD103- CD11b+ DC311. 
Of note, CX3CR1int DC showed higher expression of MHCII by flow cytometry than 
CX3CR1- DC. Also the CD64+ F4/80+ CX3CR1high macrophage population in the OSE AhRDC 
CX3CR1EGFP/+ mice expressed higher levels of MHCII and lower levels of F4/80 compared to 
the CD64+ F4/80+ CX3CR1high macrophages of OSE AhRfl/fl CX3CR1EGFP/+mice, suggesting that 
macrophages are more activated in the OSE AhRDC CX3CR1EGFP/+ mice than in control 
animals.  
 During this project CD11ctdTomato CX3CR1eGFP reporter mice were generated in order to 
visualize the APC populations in situ, which were described by flow cytometry after tissue 
digestion. CD11ctdTomato single and CD11ctdTomato CX3CR1eGFP double positive cells were mainly 
found in the LP of the small intestines while EGFP single positive cells were sparse (figure 10). 
Single TED were visualized using the same mice (figure 11). 
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4.3 OSE AHRΔDC mice produce higher amounts of IgG2a MOG antibody titers 
and IFNγ  
The protective effect of ITE in EAE was attributed to the generation of tolerogenic DC, which 
secreted less proinflammatory cytokines but expressed similar MHCI, MHCII, CD40 or CD80 
levels compared to DC obtained from vehicle treated controls.  
It was tempting to speculate that the lack of AhR in DC might increase CX3CR1int DC 
populations, which might be better equipped for luminal bacterial sampling. Thereby, the 
microbiological cues in the LP could increase and MOG specific CD4+ T cells could be better 
activated. 
Therefore, it was next assessed if the frequency of MOG specific CD4+ T cells that 
produce proinflammatory cytokines is higher in the lamina propria of OSE AhRDC mice 
compared to OSE AhRfl/fl control littermates.  
Ex vivo analysis of CD4+ T cells isolated from that OSE AHRΔDC mice showed a 
moderate increase of IFNу but not IL17 producing MOG specific T cells (figure 14D and F).  
Additionally, higher MOG specific IgG2a antibody titers were found in the serum of OSE 
AHRΔDC mice compared to control animals. These results correlate well with the higher 
production of IFNγ, known to influence immunoglobulin isotypes. Previous studies have shown 
that IFNγ inhibits IgG3, IgG2b, IgG1 and IgE secretion, whereas IgG2a production is 
enhanced279,312.  
IFNy producing T cells seem to be particular relevant for the OSE mouse model, since 
the IFNγ, but not the IL17 transcripts were increased in CNS lesions of these animals. 
Furthermore, in vitro stimulation of OSE splenocytes with MOG led to the secretion of IFNγ 
and IL17 to a lesser extent101. 
Interestingly, studies using AhR KO mice showed an increase of IFNγ production 
compared to AhR competent animals. Similar results were found at mRNA level, when AhR 
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KO lymphocytes were analyzed and presented higher IFNγ levels than the WT ones, 
suggesting  an AhR  mediated downregulation of IFNγ313.  
4.4 AhR effect on T cell differentiation 
The lack of AhR in CD4+ T cells in the OSE mice did not change spontaneous EAE 
development and severity, suggesting that physiological amounts of AhR ligands do not 
modulate MOG specific CD4+ T cells directly or effectively enough to change spontaneous 
EAE. However, different publications have suggested a direct effect of the AhR on T cell 
differentiation. 
It has been shown that AhR activation modulates in vitro Th17 differentiation and thus, 
IL17 and IL22 secretion, in splenic CD4+ T cells283 and intestinal γδ T cells133. The first 
publication showed that T cells express the AhR under Th17 polarizing conditions, whereas 
AhR deficiency reduces IL17 production of splenic naïve CD4+ T cells in vitro. In the second 
paper, it was shown a higher production of IL17 in AhR deficient γδ T cells. Moreover, results 
obtained in a model of skin inflammation support these findings showing increased IL17 levels 
in the skin of AhR KO mice314. 
The AhR has been shown to play complex roles in the differentiation of Tregs142 and 
Th17 by modulating the activation of Stat1283 and through the generation of kynurenines by 
IDO in DC scattered within the gut microenvironment135. Possibly, due to the strong 
implications of AhR signaling in IL17 producing T cells, it was unlikely that Th17 were increased 
in mice lacking AhR in DC. 
4.5 AhR repercussions on astrocytes 
Similarly, OSE mice which lacked AhR in astrocytes did not show any differences in the 
incidence of spontaneous EAE. Thus, the results presented in 3.1.2 disagree with 
Rothhammer and colleagues126, who report that astrocytes can be exploited to suppress EAE 
if activated by AhR ligands.  
  
83 Discussion 
As shown in figure 18b, an increased EAE susceptibility of vehicle treated AhRAstro 
mice was observed compared to vehicle treated AhRfl/fl mice in our Laquinimod experiments 
performed with MOG35-55 immunized animals, suggesting that the relevance of the astrocytic 
AhR in EAE might be model dependent. 
4.6 EAE incidence can be altered by modifying AhR ligands in the diet  
Although the AhR was exhaustively studied for its actions mediating the toxicity of certain 
xenobiotics, different physiological functions have been slowly unraveled in response to 
endogenous AhR ligands obtained from commensal bacteria and the diet.  
Altering the composition of one natural AhR ligand, indol-3-carbinol (I3C), the disease 
incidence significantly dropped in a spontaneous EAE model. It was also shown that the OSE 
animals submitted to the I3C enriched diet possess the necessary immune elements to start 
an immune response and are fully susceptible to develop EAE if immunized (figure 5A and B).  
Previous reports treating EAE immunized mice with potent AhR agonists obtained 
conflicting results with different outcomes depending on the mode of ligand application. For 
example, systemic administration of the high affinity AhR agonist FICZ (6-formylindolo[3,2-
b]carbazole) by i.p. injection suppressed EAE142, whereas FICZ injection (incorporated to the 
antigen and CFA emulsion) exacerbated EAE pathology and promoted a Th17 response159.  
In contrast, the i.p. injection of the endogenous AhR ligand 2-(1’H-indole-3’carbonyl)-
thiazole-4-carboxylic acid methyl ester (ITE) suppressed EAE174 and the addition of tryptophan 
to the diet, which is metabolized to a number of AhR ligands by gut microbiota, ameliorates 
actively induced EAE as well126. Ingestion of indole metabolites, phytochemicals and 
tryptophan seemed to unequivocally help to homeostasis maintenance at epithelial barriers by 
producing a vast variety of AhR ligands125,275. 
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4.7 AhR mediated effect of Laquinimod on EAE 
Laquinimod, a quinoline-3-carboxamide with immunomodulatory properties315, has been 
presumed an AhR agonist based on the induction of CYP1A1 and AhRR (AhR repressor), two 
prototypical AhR regulated genes, in a number of tissues including the CNS194.  
Daily oral treatment with Laquinimod completely abolishes the development of murine 
EAE in an AhR dependent manner, as shown by Kaye and collaborators using AhR KO and  
bone marrow chimeras194. It was previously demonstrated that the presence of AhR in the 
immune system is sufficient and necessary for Laquinimod´s actions193,194. However, the exact 
immune population that mediates Laquinimod’s therapeutic effect remains to be demonstrated. 
Furthermore, there is no evidence that AhR expression is directly required one single cell type. 
Cell specific AhR knockout mice were used in order to define which cellular players are 
relevant mediators of the therapeutic efficacy of Laquinimod, including mice devoid of AhR in 
DC, CD4+ T cells, Tregs and astrocytes (AhRDC, AhRCD4, AhRTreg, and AhRAstro). 
All cell specific AhR KO mice were significantly protected by the drug as evidenced by 
a lack or delay of EAE symptoms in treated animals. In particular, Laquinimod treated AhRCD4, 
AhRTreg, and AhRAstro mice were protected against EAE similarly to Laquinimod treated Ahrfl/fl 
controls. The initial protection of AhRDC mice against EAE was less sustained over time and 
2/3 of the animals developed EAE symptoms compared to 7% of the AhRfl/fl mice.  
If animals treated with Laquinimod developed clinical EAE at later time points, the mean 
maximum disease scores were not significantly different from water treated controls. This 
suggests that Laquinimod works better in the priming than the effector phase of EAE.  
Previous experiments using C57BL/6 mice indicate that Laquinimod directly or 
indirectly regulates T cells through its influence on APCs179,181–183. Thus, DC and T cells were 
the first compartments to be evaluated in all cell specific AhR KO mice treated with Laquinimod 
from the day of immunization.  
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Splenic Tregs were comparably induced in AhRTreg, AhRCD4 and AhRfl/fl mice by 
Laquinimod treatment. Decreased percentages of CD4+ T cells producing proinflammatory 
cytokines could be demonstrated equally well in Laquinimod treated AhRCD4 and AhRfl/fl mice. 
Nevertheless, their reduction was less impressive in AhRDC mice, suggesting that AhR 
competent DC might be required for Laquinimod to lower the percentage of CD4+ T cells 
producing proinflammatory cytokines, such as IL17. This indirect effect was astonishing given 
that Laquinimod reduced the percentage of CD11c+ MHCIIhigh DC in all Cre lines including 
treated AhRDC mice. 
AhR activation in DC has been shown to promote a tolerogenic phenotype and the 
TCCD mediated activation of the AhR induced the expression of the potent 
immunosuppressive enzyme IDO in DC316. Laquinimod therapy completely abolished EAE 
development in IDO deficient mice, demonstrating that a functional IDO1-AhR axis was not 
required. 
The absence of AhR in astrocytes did not significantly impair the efficacy of the drug 
suppressing EAE. As mentioned in the previous section, AhRΔAstro mice that were MOG 
immunized and vehicle treated developed more severe EAE compared to vehicle treated 
AhRfl/fl mice, arguing for a higher susceptibility to develop EAE.  
Supporting these data (table 22 and figure 18B), Rothhammer et al126 has previously 
shown that AhRΔAstro mice experience worsening of the EAE scores compared to control 
animals. Additionally, they used a lentivirus construct with an AhR targeting shRNA expressed 
under the control of the GFAP promoter to prove that the increase of the disease severity was 
due to lack of the expression of AhR in astrocytes and not in GFAP+ cells outside the CNS.  
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4.7.1 Laquinimod effect on NK cell cytotoxicity 
Previous results of our group demonstrated that Laquinimod effectively activates NK cells in 
vivo and in vitro. NK cells contribution to Laquinimod’s therapeutic efficacy has been observed 
in vivo by a marked reduction of the drug’s protective effect in EAE after NK cell depletion. 
Additionally, Laquinimod improved NK cell mediated killing of B16F10 melanoma cells in vitro. 
Figure 20 shows a consistent elevation of the activation marker CD69 in NK1.1+ cells 
obtained from Laquinimod treated mice from the day of immunization. However, AhR 
competent DC and CD4+ T cells were not required for NK cell activation after Laquinimod 
treatment. 
Next, the ability of Laquinimod to suppress B16F10 melanoma cell metastases was 
evaluated in vivo using preventive and therapeutic approaches. Daily oral Laquinimod 
treatment significantly decreased lung metastasis if given before B16F10 melanoma cells were 
i.v. transferred. 
Even though AhR KO mice developed less metastases than C57BL/6 controls, 
Laquinimod failed to reduce the number of B16F10 metastases further, suggesting the AhR 
mediated activation of NK cells might contribute to B16F10 metastasis control. 
It has been shown that AhR modulates the differentiation and activation of murine289 
and human317 NK cells. In humans, CD56bright NK cells were shown as highly sensitive to AhR 
ligands, which modulate their activation, receptor expression, cytokine production and 
antitumor capacity317. Besides, the expression of AhR in NK cell developmental intermediates 
regulates their interaction with conventional DC within secondary lymphoid tissue modulating 
mucosal immunity during infection292 
In mice, NK cell tumor control is significantly enhanced in vivo by administering 
endogenous AhR ligands in WT mice inoculated with murine lymphoma RMA-S cells. Such 
inhibition of tumor growth is AhR dependent because its protection is completely abolished in 
AhR KO mice. Besides, AhR deficient NK cells have reduced cytolytic activity and antitumor 
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effector functions289 and liver resident NK cells lacking AhR have an impairment of their 
maintenance and memory318. 
4.7.2 Final remarks on AhR mediated Laquinimod’s effect 
Taking all these data together leads to different possible hypotheses. For instance, 
Laquinimod’s protection could require downstream targets of AhR signaling. Due to its 
promiscuity, the AhR signaling network is involved in different cellular processes and it is able 
to activate different pathways depending on the agonist that triggered the cascade319 For 
example, Laquinimod induction of Tregs responses is probably occurring through different 
mechanisms to the AhR signaling activated by tryptophan metabolites (which induce IDO 
expression in DC and lead as well to Tregs responses)131,285,298,320.  
An alternative hypothesis would consider that Laquinimod’s protection is not limited by 
one single cell player expressing AhR but rather regulated by the interplay of different AhR 
competent cells. It is also possible that Laquinimod’s therapeutic efficacy might require AhR 
competent macrophages or B cells, which were not approached in the present thesis. 
In summary, the most likely scenario is that additional cell types are involved in 
mediating the protective efficacy of Laquinimod and that the AhR is not the only receptor 
mediating the protective effect of the drug.  
 
  
88 Outlook 
5 .  O UTLOOK 
The present thesis showed that AhR deletion in DC augments spontaneous CNS 
autoimmunity, elevates the percentage of LP CX3CR1int DC and induces a moderate increase 
of IFNγ producing MOG specific CD4+ T cells. It was also shown that dietary supplementation 
with I3C, an AhR ligand present in cruciferous vegetables, effectively suppresses spontaneous 
CNS autoimmunity of AhR competent OSE mice. In further experiments newly developed tools 
will allow us to understand the aforementioned observations better: 
In order to clarify if the AhR deficiency in DC leads to local or more disseminated 
changes in the APCs compartment, their analysis in the OSE AhRDC CX3CR1EGFP/+ and OSE 
AhRfl/fl CX3CR1EGFP/+ reporter mice will be extended to the Peyer’s patches, mesenteric lymph 
nodes and spleen.  
Subsequently, it would be interesting to characterize in more detail the AhRfl/+ 
CD11cCre+ R26ReYFP and AhRfl/- CD11cCre+ R26ReYFP mice and to further confirm the AhR 
deficiency in YFP+ DC in the latter. AhR competent or AhR deficient YFP+ DC could be sorted 
and used for RNA sequencing analyses or functional ex vivo studies with naïve MOG specific 
T cells as responders.   
Due to the changes observed in the APCs compartment of the OSE AHRΔDC 
CX3CR1EGFP/+ reporter mice, in vitro and in vivo functional studies would be desirable to test 
the APCs immunogenic capacity to prime T cells. In vivo, adoptive transfer of MOG specific 
RFP labeled Vα3.2+ CD4+ T cells into AhRfl/- CD11cCre+ R26ReYFP mice or OSE AHRΔDC 
CX3CR1EGFP/+ animals to analyze if MOG specific T cells colocalize with LP DC and 
differentiate into better cytokine producers in mice expressing AhR deficient DC. In vitro, co-
cultures of MOG specific RFP labeled Vα3.2+ CD4+ T cells and intestinal DC sorted from AhRfl/- 
CD11cCre+ R26ReYFP mice would allow to measure T cell activation and proliferation. 
This work provided compelling evidence of the regulatory role of the AhR in 
spontaneous CNS autoimmunity. It was shown that the increase of one single AhR ligand (I3C) 
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dramatically diminished disease incidence in a model of spontaneous EAE. Having available 
the molecular tools, it would be interesting to evaluate which are the most relevant cells 
mediating AhR’s actions through the diet. Therefore, following experiments aim to study the 
effect of the chemically defined diet (E1500) supplemented with I3C2mg/kg in the cell specific 
AhR KO mice (OSE AhRDC, OSE AhRCD4 and OSE AhRAstro transgenic lines). Furthermore, 
it will be investigated if the I3C supplied in the chow decreases the percentage of LP CX3CR1int 
DC obtained from the small intestines. 
Furthermore, spontaneous stool samples and the contents of the small intestines of 
OSE mice (kept under a regular, chemically defined or I3C2mg/kg enriched chemically defined 
diet) have been snap frozen during this project. The next step will be to use the samples to 
characterize the composition and differences between the gut microbiomes. 
The results obtained in this thesis indicated that Laquinimod’s protection is either 
supported by additional cell types apart from the ones studied or is conferred by an effect on 
multiple cell types simultaneously. That is why it would be necessary to test mice with AhR 
deleted in further cell types, such as B cells, macrophages and NK cells (AhRΔMac, AhRΔBcell 
and AhRΔNKcell) using the corresponding Cre lines (LysMCre, NKp46Cre and mb1Cre mice). 
Furthermore, it is likely that AhR independent effects contribute to Laquinimod’s protection 
from autoimmunity. 
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6 .  CO NCLUSIO NS 
CNS autoimmune diseases are likely caused by a complex interplay of genetic and 
environmental factors. One of the well-established environmental sensors is the aryl 
hydrocarbon receptor (AhR), which is widely expressed in the immune and central nervous 
system (CNS). The AhR is not only activated by pollutants such as TCDD but also by a number 
of physiological ligands of the diet, the commensal flora and diverse metabolites produced by 
the host.  
This study assessed if the incidence and severity of spontaneous EAE in OSE mice 
are modified by the selective deletion of AhR in immune cells (including DC, CD4+ T cells and 
Tregs) or in CNS resident cells, such as astrocytes. AhR deletion in CD11c+ cells significantly 
increased spontaneous EAE incidence in the OSE mice. In contrast, OSE animals lacking AhR 
competent CD4+ T cells, Tregs or astrocytes did not differ to OSE AhRfl/fl control littermates in 
their ability to mount a CNS autoimmune response.  
Using OSE AhRDC CX3CR1EGFP/+ reporter mice, it was demonstrated that AhR 
deficiency led to changes in the intestinal APCs by upregulating the percentage of DC 
intermediately expressing CX3CR1 (CX3CR1int DC) in the lamina propria (LP) of OSE mice. 
CX3CR1+ DC expressed higher levels of MHCII compared to CX3CR1- DC. Therefore, they 
might be better equipped to mount a CD4+ T cell response.  
Generating CD11ctdTomato CX3CR1eGFP transgenic mice, the presence of CD11c+ and 
CD11c+ CX3CR1+ double positive DC was confirmed in histological sections of the intestinal 
LP. Interestingly, a number of previous studies emphasized the unique ability of CX3CR1+ DC 
in the LP to sample gut bacteria. 
The ablation of AhR competent DC in OSE mice increased the frequency of IFNγ 
producing MOG specific CD4+ T cells in the LP and led to higher titers of MOG specific IgG2a 
antibodies in the sera of the mice. 
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Demonstrating the therapeutic potential of AhR targeted medications, the spontaneous 
EAE was almost completely abolished in OSE mice by increasing the dietary intake of one 
single AhR ligand present in cruciferous vegetables, the indol-3-carbinol (I3C). 
While AhR deletion in astrocytes did not influence spontaneous autoimmunity in the 
OSE mouse model, it worsened EAE in MOG35-55 immunized AhRAstro mice suggesting that the 
relevance of astrocytic AhR might be model dependent.  
Laquinimod is a presumed AhR agonist, which was moderately effective in reducing 
relapse rates in clinical trials with RRMS patients. Cell specific AhR knock out mice were 
generated in order to analyze which cell type is relevant for the therapeutic efficacy of 
Laquinimod to suppress EAE. Laquinimod treatment protected all cell specific AhR deficient 
mice against EAE. However, its protective effect was less sustained in AhRDC mice. Moreover, 
Laquinimod reduced the percentage of IL17 producing CD4+ T cells in AhRCD4 mice but not in 
AhRDC animals, arguing for a rather indirect effect of the drug on T cells. 
In summary, it was demonstrated that physiological concentrations of AhR ligands 
modulate spontaneous autoimmunity via AhR competent DC. Additionally, MS patients might 
benefit from increasing their dietary uptake of AhR ligands 
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